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Abstract 
The aim of this study was to review developments in glycosaminoglycan and proteoglycan 
research relevant to cartilage repair biology and in particular the treatment of osteoarthritis. 
Glycosaminoglycans decorate a diverse range of extracellular matrix and cell associated 
proteoglycans conveying structural organization and physico-chemical properties to tissues.  
They play key roles mediating cellular interactions with bioactive growth factors, cytokines 
and morphogenetic proteins, and structural fibrillar collagens, cell interactive and 
extracellular matrix proteoglycans and glycoproteins which define tissue function. 
Proteoglycan degradation detrimentally affects tissue functional properties. Therapeutic 
strategies have been developed to counter these degenerative changes. Neo-proteoglycans 
prepared from chondroitin sulfate or hyaluronan and hyaluronan or collagen-binding peptides 
emulate the interactive, water imbibing, weight bearing and surface lubricative properties of 
native proteoglycans. Many neo-proteoglycans outperform native proteoglycans in terms of 
water imbibition, matrix stabilization and resistance to proteolytic degradation. The 
biospecificity of recombinant proteoglycans however provide precise attachment to native 
target molecules. Visco-supplements augmented with growth factors/therapeutic cells, 
hyaluronan and lubricin (orthobiologicals) have the capacity to lubricate and protect cartilage, 
control inflammation and promote cartilage repair and regeneration of early cartilage lesions 
and may represent a more effective therapeutic approach to the treatment of mild to moderate 
OA and deserve further study.  
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1. Introduction 
 Articular cartilage’s functional properties as a shock absorbing weight bearing tissue 
stem from its structure and the intermolecular interactions between its constituent fibrillar 
(type I and II collagen) and lattice forming collagens (type VI collagen), cell and matrix 
proteoglycans (PGs) (biglycan, decorin, fibromodulin, lumican, perlecan and aggrecan) [1-6] 
and structural and cell attachment glycoproteins (COMP, PRELP, fibronectin, laminin, link 
protein) [7]. These cartilage component are assembled into a functional dynamic composite 
(Figure 1). Confocal immunolocalizations of some of these key extracellular matrix (ECM) 
components are presented later in this review.  
 
Figure 1.  Schematic of articular cartilage depicting the chondrocyte and the collagen, proteoglycan and 
associated matrix components synthesized and assembled to provide dynamic weight bearing and visco-elastic 
properties.  Figure modified from [8] with permission [doi:10.1038/ncprheum0216]; copyright 2006 Springer-
Nature Publishers. 
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Synovial fluid has roles in the nutrition of the articular chondrocytes by diffusive processes 
and in the lubrication of the cartilage surface which protects it from surface abrasion 
particularly in weight bearing areas not protected by the meniscal fibrocartilages interposed 
between the femur and tibia.  Hyaluronan (HA) forms massive mega Dalton sized aggregate 
structures with aggrecan stabilised by link protein.  These space-filling structures are 
entrapped within the collagenous fibrillar networks in cartilage.  HA-aggrecan aggregates 
have impressive water regain properties and these generate hydrostatic pressure within the 
tissue which equips cartilage with hydrodynamic weight bearing and visco-elastic properties. 
HA is also a key component of the synovial fluid which bathes the articular cartilage surface.  
 
 
 
Figure 2. Surface rendered 3D image of a chondron containing a chondrocyte in a fluorescent confocal image.  
The chondron is composed oft he lattice forming type VI collagen (a), perlecan surrounds the chondrocyte 
pericellularly and interacts with type VI collagen as highlighted in the co-localisation mask (b).  The perlecan C-
terminus interacts with α2β1 integrin expressed on the chondrocyte surface. Chondrocyte monolayers expressing 
perlecan in culture (c) and type XI collagen which is present as fine fibrillar material.  Perlecan interacts with 
type XI collagen and this forms a cell-ECM interconnection which facilitates communication and acts as a bio-
sensor for the chondrocyte to perceive its biomechanical micro-environment, allowing it to respond to changes in 
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the ECM orchestrating the replenishment of deficient components and facilitating homeostasis of ECM 
composition and tissue function.  Figure 2a courtesy of Dr AJ Hayes, University of Cardiff, UK Copyright AJ 
Hayes 2012 . Figure 2b reproduced with permission[9] [doi: 10.22203/eCM]2018 under the terms of licence CC-
BY-SA; 2016 with permission of the copyright holders. Fig 2c,d: Reproduced with permission from[10] [doi: 
10.1007/s10735-019-09823-1];  2019, Nature Springer Publishers under terms of license 459010123588. 
PGs and glycosaminoglycans (GAGs) have been the subject of intensive investigation in 
connective tissue biology for over ten decades.  In more recent times a major breakthrough 
came from the appreciation that PGs/GAGs were not merely supportive scaffolding 
components of the ECM. In addition to their structural roles, they are also dynamic, 
responsive, regulatory elements of the ECM and participate in cell-cell and cell-ECM 
communication, the regulation of cellular metabolism, cell proliferation and differentiation - 
duties that make them essential for normal tissue function and homeostasis[11] (Figure 2).  
This has led to the realization that PGs/GAGs could potentially be used in a therapeutic mode 
to promote repair of tissue defects[12, 13-18] and the re-attainment of functional properties in 
tissues that had undergone degradative changes due to disease [15, 17, 19, 20, 21, 22]. Articular 
cartilage has an inherently low capacity for self-repair and degeneration of cartilage in 
diseases such as osteoarthritis (OA) are painful debilitating conditions leading to considerable 
interest in repair biology for the development of therapies to prevent disease progression to 
end stage OA [23]. Articular cartilage that has undergone osteoarthritic changes is a 
particularly challenging tissue to repair and one in which major efforts have been devoted 
world-wide for over five decades but with little success. OA imposes a large and rapidly 
increasing global disease burden that is challenging global health-care systems.  Disease 
progression in OA, produces increasing pain and impaired joint function leading to the need 
for total knee joint replacement in end-stage debilitating OA. Data from the American 
Academy of Surgeons (AAOS) Annual Report in 2018 indicated OA resulted in ~160,000 
total joint replacements in England and Wales and 492,000 in the USA in 2017. The World 
Bank has calculated from United Nations Population data collected from 1960 to 2017 a 
consistent world-wide trend in ageing populations predicting a dramatic global increase in 
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individuals aged ≥ 65 year in the next two decades (https://data.worldbank.org).  Elderly OA 
prone patients will therefore represent a more significant proportion of the world population 
over the coming decades [24].  The prevalence of knee OA has doubled since the mid 20th 
century and it is predicted to become a leading global musculoskeletal condition by 2050 [25]. 
 Identification of OA as a global disorder affecting all joint tissues has partially 
explained the lack of success of therapeutic approaches which have focused specifically on 
joint-specific articular cartilage repair.  Of all of the many therapeutic approaches that have 
been examined, objectively, only one compound has achieved any success in terms of a 
recovery of joint tissue structure and function, and stimulation of resident cell populations to 
replenish joint tissues. This compound is hyaluronan (hyaluronic acid; HA), which is now 
available in many different formulations that have been used in broad and diverse applications 
with other therapeutic agents to promote joint functional properties. International guidelines 
by the Food and Drug Administration (FDA) and European Medicines Agency (EMA)-
recommend that the management of knee OA should utilise combined non-pharmacological 
and pharmacological therapeutic interventions[26, 27]. In order for such therapeutic 
formulations to be effective, ideally, they should be applied to joints in the early pre-
symptomatic stages of cartilage damage, which if left untreated have a high likelihood of 
progressing to an advanced OA phenotype.  It should be stressed that the development of a 
preventive strategy combining the natural beneficial effects of compounds which maintain the 
lubrication of the weight bearing surfaces of joints with therapeutic compounds which 
stimulate cartilage repair (orthobiologicals) is a new treatment proposal we outline in this 
review and its merits should be given due consideration.  It is the weight bearing regions of 
joints that initially develop lesions during the degeneration of knee-joint components and 
subsequent development of OA so it is logical that these regions should be the focus of any 
prospective therapeutic interventions.  Visco-supplementation is a useful effective therapeutic 
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procedure that is simple to perform.  In this review we provide evidence that visco-
supplements could be further augmented with growth factors (or PRP), neo-PGs such as 
mLUB15, a lubricin biomimetic and therapeutic stem cells to further improve the 
effectiveness of visco-supplementation raising it from a maintenance modality to one with 
positive impact on the repair of degenerate joint tissues.  While all components of this 
proposed multifunctional bioactive visco-supplement have proven effectiveness individually 
no such combination therapy has yet been examined for the treatment of OA but is certainly 
worthy of consideration and has considerable merit. A further important aspect of such a 
treatment is that for it to have optimal success it should target the earliest stages of OA lesion 
development to prevent  progression to an advanced degenerative stage and is an important 
preventative aspect of such a therapeutic approach. Treatment of joints with well-established 
advanced OA lesions, have been singularly unsuccessful.  The most appropriate therapeutic 
window to target to ensure successful treatment is clearly the earliest stages of OA.  However, 
despite advances in imaging methodology, routine identification and selection of patients with 
early OA lesions is challenging and herein lies a major difficulty when attempting to 
undertake successful therapeutic intervention.  However imaging of knee joint tissues is 
continually improving and will greatly aid in patient selection in the future when such 
improved methodologies become more widely accessible.  
 
  In articular cartilage, PGs play important and diverse multi-functional roles in the 
ECM and cell-associated environment[2, 28-32, 33, 34]. Not only do they mechanically stabilize 
the tissue, but they facilitate cell-matrix communication, acting as mechano-sensors that 
transmit sensory regulatory cues to the resident cell populations which allow them to sense 
and respond to ECM alterations and orchestrate replacement of deficient components in order 
to maintain tissue homeostasis and undertake intrinsic repair processes. These functional 
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properties are due to the PG core proteins and their attached GAG side chains. This review 
provides technical information on recombinant and synthetic neo-PGs and their prospective 
use in biomimetic procedures in repair biology [35]. 
 
1.1 Evolution of GAG  mediator/proteoglycan multifunctional effector molecules. 
 GAGs decorate the core proteins of PGs which provide additional functional attributes 
to tissues through their particular modular core protein design[36]. GAG evolution over 500 
million years of vertebrate and invertebrate evolution [37] has selected for GAGs  equipped 
with molecular recognition and information transfer properties.  These GAGs act as cellular 
mediators in the glycocalyx surrounding all cells and control responses to growth factors, 
cytokines and morphogens at the cellular boundary [38, 39, 40].  Thus GAGs and PGs evolved 
which have regulatory properties over downstream cell-signalling pathways and gene 
expression networks essential for physiological life processes. The reason GAGs and PGs 
have existed in a minimally altered form throughout evolution up to the present day despite a 
requirement for a considerable investment by the cells in the many genes encoding the 
multiple biosynthetic enzymes (eg heparan sulfate (HS) requires 20+ enzymes) required for 
GAGs and PG core proteins testifies to the importance of GAGs in cellular survival and the 
functional attributes they provide to tissues. Attempts are being made to better understand the 
glycocode of GAGs in order to better determine their specific contributions in tissue 
development and ECM remodeling since this information may be of potential application in 
repair biology [13, 14, 39-42, 43, 44].    
 
1.2 Challenges of articular cartilage repair.  
 Inspiration for the development of biomaterials that interface with cartilage has been 
derived from the cartilage ECM which is abundant in both PGs and hyaluronan (HA). PGs, 
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comprised of core proteins decorated with GAG side-chains convey structural and functional 
properties to the ECM [36]. Advances in our understanding of their biological interactions have 
demonstrated key aspects that need to be designed into cartilage-interfacing biomaterials. 
Tissue engineers have designed synthetic and semi-synthetic biopolymers for use as structural, 
chemical and biological replacements for native PGs [45-47]. These are referred to as neo-PGs 
since they serve as functional and therapeutic replacements for natural PGs currently 
unavailable for tissue engineering studies. Although limitations exist in neo-PGs in terms of 
their cell signalling capability and biocompatibility, they nevertheless display promise as 
replacements for natural PGs through their cell and protein binding properties [45]. This review 
covers recent developments in the development and application of GAG-based biomaterials in 
articular cartilage tissue engineering and also considers their roles in supporting functional 
tissue regeneration. 
2. Articular cartilage proteoglycans.   
 Approximately 45 ECM and 10 cell-associated PGs have been categorised, twelve of 
these occur in articular cartilage [36, 46, 48, 49], schematics are shown depicting the complexities  
of their structural forms (Figures 3-5).  The essential roles these PGs provide in life-processes 
has ensured their phylogenetic longevity throughout vertebrate and invertebrate evolution.  
Every cell has a surface glycocalyx containing GAG mediator molecules that control crucial 
signalling pathways involved in cellular regulation and development [50, 51]. Synthetic 
materials that mimic the multi-valency of this three-dimensional GAG microarchitecture 
may serve as important tools for deciphering and exploiting GAG regulatory properties in 
repair biology [51, 52].  Nano-scale biomatrices have been developed for studies of such 
glycocalyx interactions [51] and GAG microarrays have aided in the elucidation of GAG 
sulphation patterns required to drive such processes [53].  PGs act as ECM scaffolding 
molecules and stabilise tissues [5, 18, 30, 54]. GAG side chains in PGs are variably sulfated and 
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have interactive properties with growth factors, chemokines, cytokines, morphogenetic 
proteins and structural matrix components, which aid in the stabilization and development of 
tissues[13, 28, 39, 41, 43, 55].  
2.1  Aggrecan structure and function.  
 In many PGs the GAG side chains are heterogeneous structures which are subject to 
spatial and temporal variation in specific tissue locations in tissue development. HS 
heterogeneity and fine structure is a finely controlled process in PGs such as perlecan [56] and 
is of considerable importance in the regulation of tissue development, while the chondroitin 
sulfate (CS) chains on aggrecan are less variable in structure [57].  The density of the GAGs on 
perlecan and aggrecan also widely differ with endothelial perlecan containing typically 3 HS 
chains attached to its N-terminal domain-1 while aggrecan has ~100 CS chains variably 
distributed in its CS1 and CS2 domains located towards its C terminus, and 25-30 keratan 
sulfate (KS) chains located at the N-terminus of the CS-rich region [29] (Figure 3c).  Other 
members of the lectican PG family do not contain this KS-rich region [58]. The function of HS 
and CS differ, the fine structure of HS is critical in determining perlecan’s binding properties 
with growth factors and other mediators which initiate cell signalling [6, 59].  A comparative 
study of CS and HS in the promotion of three-dimensional chondrogenesis of mesenchymal 
stem cells (MSCs) showed that CS-hydrogels of low mechanical stiffness provide a scaffold 
which promotes MSC-based cartilage tissue regeneration.  CS was more potent at inducing 
chondrogenesis than HS [60].  The high density of the CS chains in aggrecan provide a high 
fixed charge density critical to the performance of aggrecan in water imbibition, tissue 
swelling and the generation of internal hydrostatic pressure in weight bearing tissues [61]. 
These hydrodynamic properties are described by the Gibbs-Donnan effect [62] and are a 
function of the high density of CS chains and their mutual repulsive effects on the aggrecan 
core protein and their associated counter-ions and how these partition in cartilaginous tissues 
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due to osmotically-driven forces. This partitioning effect provides an internal hydrostatic 
pressure which provides weight bearing properties to articular cartilage and intervertebral disc. 
Less is known of the specific contribution which the KS chains make to aggrecan’s functional 
properties however like the CS chains they may also contribute to water imbibition to some 
extent however the need for two different GAGs on the aggrecan core protein is unclear  
(Table 1).  The KS domain in aggrecan (KS rich region) is located between the G2 and CS 
rich domains, and is encoded by exon 11. However the amino acid sequence in this domain 
region varies among species and this has consequences on the relative KS contents of 
aggrecan in these species. Some of these species like rodents are frequently used in animal 
models of human disease however rodent aggrecan is devoid of a KS rich region and findings 
with these models therefore need to be carefully interpreted. The consensus sequence for 
attachment of KS in human aggrecan core protein is E-(E,K)-P-F-P-S or E-E-P-(S,F)-P-S [63, 
64].  In humans and cows, aggrecan contains a segment of 4–23 such hexapeptide repeats 
where the KS chains are located, rats and other rodents lack this motif and do not contain KS 
[63].  The rodent aggrecan core protein is truncated in the KS rich region and rodent aggrecan 
does not contain a KS rich region equivalent to that found in human or bovine aggrecan.  This 
does not appear detrimental to aggrecan turnover or aggrecan’s functional properties in rodent 
cartilages thus it is uncertain what the role of the KS chains on the aggrecan core protein is.   
Rodent aggrecan does contain small N- and O- linked KS chains in the G1, G2 and IGD and 
these have been suggested to potentiate aggrecanolysis by ADAMTS metalloproteases [65] 
which are important in the normal turnover of this PG in cartilage.  ADAMTS-1-knockout 
mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo [66].  ADAMTS-5 is 
the major aggrecanolytic enzyme in mouse cartilage and has roles in skeletogenesis and in the 
development of OA [67].  However, using mice lacking ADAMTS-5 activity it has been 
possible to identify additional genes involved in the initiation of OA which are responsible for 
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cartilage destruction.  These act independently of ADAMTS-5 in post traumatic models of 
OA in mice [68]. Aggrecan mimetic neo-PGs have been prepared using CS and the absence of 
KS in these molecules is not apparently detrimental to their performance.   
 
 
Figure 3. Composite figure depicting the spatial orientation of the petal distibution of the Australian bottlebrush 
Callistomine rigidis (a, b) which have been compared with the GAG chains oriented around and distributed 
along the aggrecan core protein (c). The aggrecan core protein contains three globular domains G1, G2, G3, KS 
rich region and CS1 and CS2 chains attached to a central core protein (c).  The aggrecan core protein is 
susceptible to cleavage by MMPs and ADAMTS-4, 5 (aggrecanase-1, 2).  These core protein cleavage sites are 
indicated as arrows 1-14. Despite the massive literature on aggrecan several aspects of its KS chains remains 
unresolved.  These areas of interest in the G1, interglobular, G2, KS rich and CS1 and CS2 regions are indicated 
*P$
JP$
(P$ CP$
-P$$ :P$$
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with the labelled points (1-4) which are discussed further in the text. Schematic depiction of the aggrecan-HA-
link protein ternary complex which is found entrapped within type II collagen networks in cartilaginous matrices 
and provides the hydrodynamic properties of weight bearing tissues (d).  Matrix components which interact with 
aggrecans G3 domain include type VI collagen, cartilage oligomeric protein (COMP), decorin and biglycan 
which assemble extended networks between aggrecan macroaggregates and collagen networks in tissues (d).  
Similar protective perineural net structures assembled from the lectican proteoglycan family and HA also occur 
in the CNS/PNS.  These so called perineuronal nets are visualized by immunolocalization of MAb 1B5 (+) 
epitope in rat brain (e) and pericellular 1B5(+) epitope expression by isolated neurons (f).  Scale bars 100 µm.  
Fig 3e, f courtesy of Dr Anthony J. Hayes and Prof Bruce Caterson, Cardiff School of Biosciences, University of 
Cardiff, UK.  Copyright B. Caterson 2006. Antibodies provided courtesy of Professor Bruce Caterson, Cardiff 
University, Cardiff, UK. 
 
Table 1. How Do The KS Side Chains of Aggrecan Contribute To Its Structure and Function 
(* For an explanation of features 1-4 see Figure 3c) 
Feature* Functional contributions 
1 
G1, G2 
and IGD 
regions 
The functions of the small N- and O- linked KS chains in the IGD, G1 and G2 
domains of aggrecan are largely unknown.  The IGD KS chains may potentiate 
and initiate cleavages in the aggrecan core protein by ADAMTS-4 and ADAMTS-
5. KS chains in the G1 domain obscure a T cell epitope which otherwise makes the 
G1 a powerful arthritogen in auto-immune models of inflammatory arthritis.  
2 
G2 
region 
The G2 globular domain of aggrecan shares homology with its G1 domain but 
does not bind HA and the biological role of the G2 domain is unknown. 
3 
KS rich 
region 
The function of the O-linked KS chains in the KS rich region of human aggrecan is 
not known.  These are absent in murine aggrecan with no obvious detrimental 
effect on cartilage function and aggrecan turnover. 
 
 
4 
CS1 rich 
CS2 rich 
regions 
KS chains are sparsely distributed in the CS2 region and are end-capped with L-
Fucose and N-acetyl neuraminic acid.  These KS chains are antigenically distinct 
from KS chains of the KS rich region.  The KS chains in aggrecan isolated from 
non-weight-bearing nasal, laryngeal and tracheal cartilages do not contain such 
capping structures on KS thus their functions are unknown.  In contrast the KS 
chains of aggrecan in amyotrophic lateral sclerosis (ALS) in brain tissues are 
heavily substituted with fucose and sialic acid and this may modulate ligand 
binding in the PGs these modified KS chains are attached to and may alter the 
turnover of these KS-PGs in brain tissues contributing to motor neuron 
impairment. 
 
2.2   The cartilage proteoglycans.   
 Cartilage contains a number of large and small ECM and pericellular matrix (PCM) 
proteoglycans  as well as transmembrane PGs attached to the chondrocyte cell surface. These 
have been recently reviewed [13, 15, 36, 69].  As already noted, aggrecan is the major cartilage PG 
responsible for the imbibition of water into cartilage which is the basis of cartilages ability to 
act as a weight bearing tissue (Figure 3), perlecan is also a prominent pericellular PG (Figure 
  
14 
 
4).  A layer of chondrocytes at the cell surface of flattened morphology also synthesise a large 
400 kDa CS-PG, versican as well as a 345 kDa mucin-like proteoglycan called lubricin 
(proteoglycan 4, PRG4) (Figure 5d).  This was also previously known as surface zone protein 
or megakaryocyte stimulating factor.  Versican interacts with HA via its globular (G1) HA 
binding  domain localising HA at the surface of cartilage where along with lubricin it is 
responsible for the near frictionless articulatory properties of articular cartilage [70, 71].  The 
lubricin core protein has somatomedin B, heparin-binding and hemopexin domains and a 
mucin  rich region which is heavily glycosylated with more than 168 O-linked  glycan chains.  
Some of these mucin chains are also substituted with sialic acid [70].  Lubricin also contains a 
small CS chain thus should more correctly be considered a glycoprotein rather than a PG [71]. 
Some lubricins do not contain this CS chain [72].  Lubricin is discussed more fully later in this 
review.   
 
 Cartilage also contains two large basement membrane HS-PGs, perlecan (Figure 4a) 
and agrin (Figure 5d) and two families of cell-associated HS-PGs, the glypicans and 
syndecans [30, 33, 73]. Perlecan is a prominent modular, multifunctional pericellular PG which 
promotes chondrogenesis, matrix stabilisation, chondrocyte differentiation and growth factor 
signalling and has an extensive repertoire of interactive ligands (Figure 4).  Perlecan has a 
467 kDa core protein which contains 3 GAG chains in domain I.  In endothelial cells perlecan 
contains three HS chains, whereas in chondrocyte perlecan up to two of these HS chains are 
replaced by CS.  The CS chains of chondrocyte perlecan contain 4, 6-disulfated motifs which 
direct collagen fibrillogenesis [2, 4-6, 74].    
 
 Agrin is a 400 kDa HS-PG of basement membranes which interacts with low-density 
lipoprotein receptor-related protein-4 (LRP4) and α-dystroglycan in chondrogenic signalling 
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networks supporting chondrocyte differentiation and the upregulation of SOX9 and its 
transcriptional targets, COL2A1 and ACAN [75] (Figure 5e). Agrin-induced chondrocyte 
differentiation does not induce hypertrophy. LRP4 interacts with WNTs and BMPs [76]  to 
regulate chondrocyte differentiation.  Agrin has not been evaluated in cartilage repair 
strategies. Cartilage also contains several members of the small leucine rich proteoglycan 
(SLRP) family including the CS or DS-substituted decorin and biglycan and the KS 
substituted lumican, fibromodulin and keratocan[33, 77].   
 
 The SLRPs are horse-shoe shaped proteins which have a central region containing 
multiple leucine rich repeat (LRR) domains which are interactive with a wide range of 
proteins, another characteristic of the SLRPs are N-and C- terminal disulphide-stabilised 
globular domains.  Decorin and biglycan contain one or two O-linked GAG chains attached to 
their N-termini (Figure 5b, c).  Lumican, fibromodulin and keratocan have 3-4 N-linked KS 
chains located within their LRR regions.  The SLRPs bind to fibrillar collagens and regulate 
the fibrillogenesis process. The SLRPs regulate tissue organization, cellular proliferation, 
adhesion, and responses to growth factors and cytokines [77] in inflammation [16], cell growth, 
tissue morphogenesis and innate immunity [21, 78]. Biglycan acts as a pathogen associated 
molecular pattern (PAMP)-like ligand interacting with toll-like receptor-2 and -4 (TLR2 and 
TLR4) [19, 78] and also interact with BMP/TGF-β to modulate fibrosis [79] and cell 
differentiation [21, 78].  While biglycan can interact with extracellular fibrillar collagens [80] and 
pericellular type VI collagen, its major interactive areas actually lie in cell mediated 
regulatory processes, whereas decorin has more prominent roles in collagen fibrillogenesis. 
With cartilage degeneration in the development of OA the SLRPs become progressively 
fragmented and their functional properties are lost from this tissue [1, 81].  The SLRPs are 
discussed further later in this review in the context of cartilage repair strategies. 
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Figure 4. Schematic representation of the modular structural features of the heparan sulfate proteoglycan, 
perlecan showing its five domains (a) and HS attachment region and some of the known protease cleavage sites 
(b, e).  Diagrams of recombinant domain-I (c) and domain V are also shown (d). 
 
 A further small PG found in cartilage is bikunun (Figure 5a).  Bikunin, is an ancient 
Kunitz BPTI-like serine protease inhibitor of the inter-α-trypsin inhibitor (ITI) superfamily 
and pleiotropic cell regulatory PG.  Bikunin contains one CS chain and is unique among the 
PGs in that this CS chain does not merely decorate the PG core protein but it also acts as an 
intramolecular linkage module for the attachment of a number of heavy chain (HC) proteins 
in ITI which are transferred to HA in particular cellular contexts leading to stabilization of the 
HA [82] up to six HCs can be attached to the CS chain of bikunin/ITI with tissue development 
and pathology [83]. This transfer of the HCs to HA occurs by a process of trans-esterification 
catalysed by the enzyme TSG-6 [84] and apparently stabilizes the HA countering its 
depolymerisation by free radicals released by inflammatory cells during OA and rheumatoid 
arthritis (RA)[84].  Such condensed HA in growth plate cartilage appears important in the 
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cartilage to bone transition during endochondral ossification[3]. Chondrocytes synththesize 
bikunin, its affinity for HA may localize bikunin in the surface regions of cartilage where HA 
is localized[85].  A number of catabolic proteases produced by leucocytes and mast cells 
released at sites of inflammation  (leucocyte elastase, cathepsin G, chymase, tryptase) can 
digest lubricin [85, 86]but are inhibited by ITI thus bikunin/ITI has a protective role to play at 
the cartilage surface. 
 
2.3 GAG heterogeneity and complexity confer inherent difficulties in their analysis.   
 The structural complexity and poly-dispersity of GAGs confounds their sequencing 
and structural analysis. Routine analysis of the GAG chains in PGs typically involves 
compositional and disaccharide analysis, mapping of 4-8 oligosaccharide segments and 
occasionally domain analysis, however extensive sequencing is not normally undertaken.  
Sequencing of GAGs is not a facile process and most laboratories do not have the expertise 
available to routinely undertake such procedures, however it is critical that such information 
should be known if the binding properties of native GAG chains are to be replicated [87, 88].  
Embedded sulphation motifs such as CS-D and CS-E internally in the CS chains have growth 
factor interactive properties, the surrounding regions of the CS chain serve a carrier function 
for these biological motifs [89].  Such motifs can be relatively minor components thus their 
presence is not readily detected by conventional compositional analyses.  Glycan sequencing 
methodology is steadily improving and it is now possible to sequence small GAG samples, 
however this still cannot be considered a routine procedure.  Technological advances in mass 
spectroscopy are also improving such determinations  [55, 88, 90, 91] 
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Figure 5. Schematic representation of the structure of bikunin, the simplest PG which is produced by 
chondrocytes and shows an affinity for HA thus it becomes localized at the cartilage surface (a) and the small 
leucine repeat PGs decorin (b) and biglycan (c).  Lubricin (PRG4) is a mucin-like glycoprotein which provides 
boundary lubricative properties at the surface of articular cartilage (d).  Agrin is HSPG synthesized by articular 
chondrocytes (e).  Figure reproduced from [13] with permission Biochem J. Copyright Biochem J. 2018. 
 
2.4. Functional organization of articular cartilage 
 The schematic organization of the major cartilage PGs and collagens (Figure 1), and 
chondrocyte PCM depicting type VI and XI collagen and perlecan in the pericellular 
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environment around a chondrocyte (Figure 2) demonstrates the complex inter-relationships 
between these components.  Confocal imaging of whole thickness bovine articular cartilage 
further shows the distribution of aggrecan and perlecan throughout articular cartilage (Figure 
6).  Monoclonal antibodies (MAbs)  to the core proteins of these PGs and MAb 4C3 to a CS 
sulphation motif  co-localised these PGs throughout the articular cartilage (Figure 6a, b).  
Use of a white overlay clearly delineates the pericellular colocalisation of these components 
(Figure 6b). Type I Collagen is immunolocalised to the surface regions of cartilage where it 
provides resistance to tensional shear loads (Figure 7a) whereas type II collagen is 
immunolocalised throughout the full depth of the cartilage (Figure 7b). Type II collagen and 
supramolecular aggregates of aggrecan and HA, stabilized through link protein, make up the 
bulk of the tissue (Figure 7b), endowing it with its unique hydration properties to resist 
compressive loading. Aggrecan, a hyalectin containing CS and KS GAG chains, is abundant 
in cartilage  and, like type II collagen, is a primary chondrogenic marker (Figure 6a). 
Perlecan, a modular, multi-functional heparan sulfate (HS)/CS PG is also a marker of early 
chondrogenesis in cartilage rudiments [3, 4] and a stem cell niche component (Figure 6b). The 
CS GAG chains of aggrecan carry unique sulphation motif epitopes, which facilitate 
interaction with  growth factors and cytokines [6, 31, 92].  Versican is more typical of tensional 
fibrocartilaginous tissues such as meniscus, tendon or annulus fibrosus but can also be 
expressed by some chondrocytes with a flattened morphology in the cartilage surface regions 
(Figure 8a).   Fluorescent colocalisation of aggrecan (identified by MAb 6B4) and perlecan 
(MAb 1948) with CS sulphation motifs recognized by MAb 4C3 demonstrated that both PGs 
are substituted with 4C3 and have overlapping distributions in the pericellular chondrocyte 
environment further illustrated via the white overlay mask depicted (Figure 6b).  Versican, a 
CS hyalectin typical of tensional fibrous/fibrocartilaginous tissues such as meniscus, tendon 
or annulus fibrosus, was also expressed in superficial articular cartilage; however it was not 
associated with the 4C3 CS motif (Figure 8a) [93].  Versican and aggrecan both form ternary 
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complexes with HA and link protein in articular cartilage.  Versican may have specific roles 
to play in the localization of HA at the articular surface [93].  Aggrecan, however, has a more 
widespread distribution, like perlecan, throughout the cartilage matrix which experiences 
compressive loading.  Both of these PGs have biomechanical attributes which allow the 
cartilage to withstand compression. Perlecan is pericellularly distributed around chondrocytes 
along with type VI collagen providing compliancy to the rigid type VI collagen lattice.  
Perlecan compliant properties are considered cyto-protective in tensional and weight bearing 
tissues [2, 9, 94]. Lubricin (proteoglycan-4, PRG4) has a distinctive localisation at the articular 
surface, hence is also commonly referred to as surface zone proteoglycan (SZP) (Figure 8b). 
Lubricin interacts with HA, cartilage oligomeric matrix protein (COMP) and fibronectin, and 
[95] contributes to the lubrication and protection of the articular surface from mechanical 
damage and chondrocyte apoptosis [34, 96] thus protecting against the development of OA 
(Figure 8b).  Mechanical damage to articular cartilage modulates lubricin biosynthesis [97].  In 
a meniscectomy model of OA in sheep, lubricin levels are significantly down-regulated [98]. In 
mice lacking PRG4 a loss of articular cartilage structure, stiffness and boundary lubrication 
severely depressed the articulatory properties of murine knee joints [99]. The above studies 
show a direct inter-relationship between lubricin, boundary lubrication, and cell survival 
suggesting that supplementation of synovial fluid or a visco-supplement with HA 
and lubricin could prevent further cartilage deterioration in OA and provide conditions 
conducive to intrinsic cartilage repair [100].  Gene therapy which upregulates PRG4 expression 
[101] and its beneficial autocrine effects on synoviocyte metabolism [102] is consistent with the 
cartilage protection afforded by recombinant PRG4 in a porcine meniscectomy model of OA 
[103].  Biglycan, a small leucine rich proteoglycan (SLRP) with two CS/DS GAG chains, also 
has a prominent pericellular immunolocalization pattern in articular cartilage (Figure 9a) 
while decorin, has a single CS or DS chain and is distributed more prominently in the inter-
territorial matrix (Figure 9b). Decorin has important roles in the regulation of fibrillar 
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collagens [104], its incorporation into bioscaffolds promotes attachment of endothelial cells [105], 
however  neither recombinant decorin [106] or biglycan [107] have so far been used specifically 
in articular cartilage repair strategies.  Biglycan shows promise in bone repair strategies with 
BMP-2 and BMP-4 [107, 108] while decorin is implicated in the activation of growth factor and 
cytokine regulatory pathways in chondrogenic differentiation relevant to cartilage remodelling 
[109].   
 
 HA, the only GAG member which occurs devoid of a PG core protein, is non sulfated 
and has a relatively simple structure composed of the repeating disaccharide D-glucuronic 
acid (GlcA) glycosidically linked to the amino sugar N-acetyl glucosamine (GlcNAc).  This 
simplicity in structural design hides the complexity of HA’s cell regulatory properties [110]. 
HA evolved as a molecule which avoided immune detection and has been referred to as a 
stealth molecule [111] with material properties which provide hydration to tissues conducive to 
cellular survival and cellular migration in tissue development [112]. Cross-linked HA has been 
developed as a drug delivery vehicle and various formulations of HA have been used to 
deliver therapeutic stem cell preparations [113, 114].  Besides its application to combat OA and 
preserve joint function, HA preparations have also found widespread application in 
ophthalmic surgery, and embryo implantation procedures [115]. HA has also been widely used 
as a delivery vehicle in ophthalmic, nasal, pulmonary, parenteral, implant and gene transfer 
procedures [115] and in the development of smart new-generation multi-lamellar wound 
dressings (Hyalomatrix(®)[116].  HA has also been used as a nano-particle delivery vehicle for 
drugs, RNA, DNA and growth factors [117-119]. Nano-particles coated in HA have anti-
inflammatory and ROS scavenging properties [120].  The free radical scavenging and anti-
oxidant properties of HA have also been applied to new generation smart wound dressings [22, 
54, 121]. HA is discussed more fully later in this review. 
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 The ability of native HA to convey cell regulatory properties is doubly surprising 
given its lack of sulphation. The CS sulphation motifs have information and cell regulatory 
properties similar to other GAGs [13, 39, 48, 122, 123].  HA has important progenitor cell regulatory 
properties operative in embryonic and foetal development and is a common component of 
stem cell niches. It also has functional roles to play in the formation of macromolecular 
assemblies with aggrecan in mature cartilaginous tissues and with the lectican PG family in 
perineuronal nets [13, 32, 58, 124].  HA also supports the lubrication of articular cartilage surfaces 
in synovial joints [125]. Many PGs have interactive properties with HA that are important to 
tissue function and this is a trait that has been built into many neo-PGs by the incorporation of 
HA-binding peptides (HABPs) [45, 126]. HABPs are prominent components of the neo-PGs, 
mAGC and mLUB15 which are analogue forms of aggrecan and PRG4 and these make 
critical contributions to the water regain and tissue lubrication properties of cartilage.  These 
traits are discussed in detail later in this review.    
 
3. Application of proteoglycans in cartilage tissue engineering 
 Current attempts to regenerate articular cartilage aim to produce biological and 
functional neo-cartilage with an articular surface similar to that of the native tissue [127].  
However a cartilage-centric approach may be short sighted and is liable to be unsuccessful in 
terms of the function of the whole joint unless the global health of all joint tissues are 
successfully addressed. Despite the major focus in OA being on the articular cartilage,  
meniscal degeneration is also highly prevalent, with pathological changes in menisci 
preceding those of articular cartilage [128, 129, 130].  Meniscal degeneration results in the 
generation of degradative proteases which contribute significantly to the total degradative 
enzyme pool in the joint synovial fluid.  Many of these degenerative changes in joint tissues  
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are also reproduced in animal models of OA, allowing specific testing of particular 
parameters or components [131].  In-vitro approaches specifically examining features of 
meniscal pathobiology have also demonstrated focal tissue changes in response to stimulation 
by IL-1 and TNFα [129, 130, 132]. Articular chondrocytes are also responsive to these 
inflammatory mediators but to a lesser extent [129].  Just as PGs are now appreciated to be 
multi-functional proteins with additional ECM stabilising and space-filling supportive roles, 
functional roles for visco-supplement polymers other than in boundary lubrication and joint 
articulation also need to be considered [133, 134].  High molecular weight HA is an efficient 
visco-supplement but in combination with PRG4 improved boundary lubrication has been 
demonstrated [133].  PRG4 like HA also has anti-inflammatory [133] and cell directive properties. 
High molecular weight HA has chondro-protective properties through its ability to inhibit 
degradative MMP production by chondrocytes stimulated with inflammatory mediators [135] 
and also modulate synoviocytes within the joint [102].  Alkyl HA derivatives are also effective 
at inhibiting MMP production and activation [136].    
 
 PRG4 localises HA at the articular cartilage surface and promotes boundary 
lubrication but also inhibits attachment of immune cells which could lead to local 
inflammatory conditions causing depolymerisation of HA and impaired joint lubrication [96, 100, 
103, 137, 138].  Thus novel formulations of visco-supplements incorporating HA and PRG4 are 
worthy of further evaluation and may have a global joint protective effect in OA.  The 
synergism of PRG4 and HA in joint lubrication [100, 139], chondro-protective efficacy of PRG4 
in a model of OA [103] and in the regulation of inflammation/innate immunity in the joint [96, 
138, 140], has already been established.  There is a great need for such globally-effective 
preventative therapeutic interventions to prevent the formation of more extensive deep 
cartilage defects that are extremely difficult to treat clinically[133]. A multi-functional visco-
supplement approach to the treatment of OA is a novel strategy which deserves further 
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evaluation in the experimental systems described above and in vivo [134]. Supplementation of 
HA with platelet rich plasma (PRP) is an early attempt to improve the therapeutic properties 
of such formulations with growth factors and other biofactors which promote articular 
cartilage regeneration (Table 4). 
 
Figure 6. Confocal co-localizations in vertical bovine articular cartilage sections using monoclonal antibody 
(MAb) 4C3 and proteoglycan core protein antibodies comparing chondroitin sulfate (CS) sulphation motif 
epitopes in aggrecan and perlecan. (a) Confocal images depict immunolocalizations of aggrecan and perlecan 
core proteins (green) and native CS motifs detected using MAb 4C3 (red). (b) Cytofluorograms showing the 
frequency distributions of the fluorescent intensities of the green and red fluorochrome channels. Co-localized 
pixels, are also depicted below this using a white overlay mask on the underlying cartilage images. A diagram of 
the 4C3 CS epitope is depicted (c). Scale bar = 25 µm.  Fig 6a,b reproduced (adapted) from [141] [doi 
10.1042/BCJ20180283]; 2008, with  permission of SAGE Publishers.  
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Figure 7. Fluorescent immunolocalizations of type I collagen (a) and type II collagen in full thickness bovine 
articular cartilage (b).  Fig 7a, b courtesy of Dr. Anthony J Hayes, Cardiff School of Biosciences, Cardiff 
University, UK. Copyright AJ Hayes 2012. Scale bars represent 50µm. 
 
3.1 Recombinant proteoglycans.  
The production of recombinant PGs which faithfully reproduce the native PG and GAG 
structure is a technically demanding task [47].  A number of recombinant PGs have been 
successfully produced [46, 142]. Reproducing GAG fine structures attached to recombinant core 
proteins to recapitulate native GAG structure is a challenging exercise. Production of 
recombinant, large PGs such as aggrecan and perlecan have their own technical difficulties 
associated with their massive molecular dimensions and glycosylation characteristics.  In the 
case of aggrecan, its high degree of GAG substitution represents around 90% of its mass and 
is of functional importance in water imbibition, space-filling and hydrodynamic properties 
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which equip tissues with their unique weight bearing properties [30, 46].  The stability of 
recombinant large PGs is also relevant to any prospective therapeutic application and it may 
be more expedient to use specific modules of the large PG in specific applications rather than 
the intact PG.  These individual modules are also simpler to synthesize and may have better 
stability properties.  Recombinant aggrecan has been prepared in a number of studies 
[reviewed in [46] however the GAG side chains of these recombinant proteins have not been a 
major focus in many of these studies and it is not clear to what extent the extensive GAG 
substitution of native aggrecan has been reproduced.   A major focus of many research groups 
has therefore been to produce aggrecan mimetic analogue molecules to overcome these 
difficulties.  Neo-aggrecans are discussed fully later in this review. 
 
Figure 8. Surface localisation of versican using MAb 12C5 to the HA binding region of versican (Iowa 
Hybridoma Bank, USA)(a) and lubricin (PRG4) using MAb 3A4 (b). Fig 8a reproduced (adapted) from [141] [doi 
10.1369/jhc.7A7320.2007]; 2008, SAGE Publishers.  Figure 8b courtesy of Prof Bruce Caterson and Dr Anthony 
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J. Hayes, Cardiff School of Biosciences, Cardiff University, UK. Copyright B. Caterson 2014.  Scale bars 
represent 50µm. 
 
The human HSPG2 gene on chromosome 1 covers 115,000 base pairs. The transcript contains  
97 exons and is 14,327 base pairs in length. Recombinant approaches with perlecan have 
produced individual domains or clusters of modules [143-147] or perlecan sequence-containing 
peptides [148]. Endorepellin is an 85-kDa recombinant fragment of perlecan domain V.  
Perlecan domain V contains four EGF-like repeats and three laminin-like globular domains 
(LG1–3).  Two EGF-like repeats separate the LG2 and LG3 domains.  Perlecan contains five 
modular domains (Figure 4a, b) and is the largest PG which has been fully cloned and 
sequenced with a core protein of 467 kDa [149], displaying homology to structural 
glycoproteins with known functional properties in matrix assembly and stabilization, 
angiogenesis, chondrogenesis and in cellular attachment [6] (Figure 4).  Rather than producing 
the perlecan core protein in its entirety the major focus in repair biology has been to 
concentrate on production of particular domains of perlecan for specific applications in repair 
biology (Figure 4c, d, ; Table 2). 
 Delivery of growth factors to tissues is hindered by their relative instability, the GAG 
side chains of PGs like aggrecan and perlecan which the growth factors bind to stabilizes and 
protects the growth factors from degradation in-situ. PGs in the PCM and ECM thus provide a 
stabilised local growth factor reservoir that can be accessed by the resident cells to undertake 
tissue homeostasis or for tissue remodelling during a wound healing response. GAGs also 
regulate growth factor-receptor interactions at the cell surface. The development of neo-
aggrecan nanoparticles as growth factor delivery platforms mimics the growth factor binding 
and stabilization afforded by native aggrecan with growth factors retaining activity for more 
than three weeks and CS-based neo-aggrecans are as effective as native aggrecan [117].  CS 
bioscaffolds have also been developed which provide instructive cues to progenitor cells and 
have been applied in a number of tissue repair applications, reviewed in [47, 150]. Perlecan 
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domain I has been conjugated to HA hydrogels and used to promote chondrogenesis through 
delivery of BMP-2 [151]. BMP-2 delivery by perlecan domain I also promotes osteogenesis [146] 
and cartilage repair in a murine model of OA [152].  Soluble perlecan domain-I increases 
VEGF-165 receptor phosphorylation by bone marrow endothelial cells [153].  Recombinant 
perlecan domain-I can also be used for FGF-2 delivery [91]. All five domains of perlecan have 
been recombinantly produced and these fragments have been shown to retain the interactive 
properties of the native molecule (Table 2). Most of the tissue repair strategies which have 
been developed with these fragments have focussed on perlecan domain-I and domain-V.  As 
already mentioned, perlecan domain-I has been used to promote chondrogenesis and 
osteogenesis [146, 151, 152, 154, 155].  Pre-clinical studies show that domain V of perlecan contains 
modules which interact with α2β1 integrin and disrupt tube formation by endothelial cells 
inhibiting angiogenesis [156].  Domain V also inhibits amyloid-β Induced activation of α2β1 
integrin-mediated neurotoxicity [157] and inhibits amyloid-β induced brain endothelial cell 
toxicity restoring angiogenic functions [158].  Domain V shows promise in the treatment of 
stroke victims [159], in the treatment of post-ischemic cerebral angiogenesis [160] and in the 
treatment of vascular dementia [161]. 
 Recombinant PGs show much promise, however they are not without limitations.  
These include expense of production at a commercial level, and the high fidelity reproduction 
of native GAG side chain fine structures.  Some GAGs require the biosynthetic machinery 
only found in mammalian cells for GAG biosynthesis and thus the non-mammalian 
expression systems often used in recombinant protein technology are unsuitable for their 
production. These are impediments to the routine cost-effective production and use of 
recombinant PGs in tissue engineering.  It is implicit in any design plan that in order to 
reproduce the precise GAG side chain microstructure of a native PG consistently then its 
GAG side chain sequence and distribution pattern along the PG core protein must have been 
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fully determined. A number of polymers act as structural, chemical and biological PG 
mimetics, or neo-PGs.  Given the expense and greater technical requirements in their 
production, recombinant PGs or modular domains of these PGs are less likely to be used in a 
generic manner but may be useful to target specific areas of tissue repair while neo-PGs do 
not specifically target specific physiological events or disease processes but are cheaper and 
easier to produce.   
3.2 Biomimetic neo-PGs.  
Neo-PG core structures attached to scaffolds have their own intrinsic limitations based on 
potential toxic side effects of the associated scaffold components [162]. Some nano-materials 
can display unexpected redox regulatory properties and detrimental oxidative effects on 
mitochondria [163], nevertheless neo-PGs and GAGs in bio-scaffolds can provide positive 
attributes in tissue engineering aiding in cellular proliferation and migration, acting as 
anchoring modules for the scaffold to tissue components and for cells to the scaffold. GAGs 
incorporated into bioscaffolds can thus sequester bioactive signaling molecules, minerals, 
growth factors and cytokines in a similar way to natural PGs [13]. Despite their limitations, the 
ease of preparation and versatile structural modification of neo-PGs that are possible makes 
these components flexible alternatives to natural and recombinant PGs for the preparation of 
tissue engineering scaffolds.  
3.3 GAG-biomaterials versus native PGs. 
 Many GAG bio-scaffolds have been developed and shown to have utility in a diverse 
range of tissue repair strategies [47] and these have provided invaluable insights as to how 
specific GAGs direct cellular behaviour to effect connective tissue repair[22],  An important 
aspect of PGs which is not reproduced to the same degree in artificial scaffolds decorated with 
GAGs is the bio-integration of these therapeutic agents in tissue repair settings. The 
functional properties of PGs is due not only to the fine structure and density of their attached 
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GAG side chains but also to functional domains within the PG core protein which also have 
an extensive range of interactive properties with many ECM components [6, 31].  These 
interactions not only stabilize the ECM but also serve to bio-integrate the PG with the tissue 
repair zone [142]. 
 
Figure 9. Immunofluorescent localisations of biglycan (a) and decorin (b) in vertically sectioned bovine articular 
cartilage showing biglycan distributed as a pericellular component while decorin is more prominent in the inter-
territorial matrix.  Nuclei were counter-stained red with propidium iodide.  Scale bar 25 mm.  Fig 9a, b 
reproduced (adapted) from [164] [doi: 10.1016/j.ymeth.2008.01.011], 2008, Elsevier Publishers under terms of 
license 4587040979458. 
 
 
 
                                 Table 2.  Features of Recombinant Perlecan Domains 
Domain Domain features Ref 
I Contains GAG attachment sites for 3 HS or CS/HS chains [146, 147] 
Fig. 4. Immuno-labelling of extracellular matrix molecules (green) at the cartilage-bone interface of young bovine articular cartilage. (A) Collagen type I.
(B) Collagen type II. (C) Collagen type X. (D) Aggrecan. (E) Biglycan. (F) Decorin. (G) Chondroitin-0-sulphate, (H) Chondroitin-4-sulphate, (I)
Chondroitin-6-sulphate, (J) Keratan sulphate, (K) Mouse immunoglobulin (negative control). Cell nuclei depicted in red. (L) Endogenous alkaline
phosphatase staining (scarlet red) associated with hypertrophic chondrocytes in the calcified zone of the tissue. Proteoglycans stained blue (alcian blue, pH
2.5). (D), (E) and (K) have been reproduced, with permission, from [25].
A.J. Hayes et al. /Methods 45 (2008) 10–21 15
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Fig. 4. Immuno-labelling of extracellular matrix molecules (green) at the cartilage-bone interface of young bovine articular cartilage. (A) Collagen type I.
(B) Collagen type II. (C) Collagen type X. (D) Aggrecan. (E) Biglycan. (F) Decorin. (G) Chondroitin-0-sulphate, (H) Chondroitin-4-sulphate, (I)
Chondroitin-6-sulphate, (J) Keratan sulphate, (K) Mouse immunoglobulin (negative control). Cell nuclei depicted in red. (L) Endogenous alkaline
phosphatase staining (scarlet red) associated with hypertrophic chondrocytes in the calcified zone of the tissue. Proteoglycans stained blue (alcian blue, pH
2.5). (D), (E) and (K) have been reproduced, with permission, from [25].
A.J. Hayes et al. /Methods 45 (2008) 10–21 15
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II Contains LDL-like receptor  [145] 
III RGDS containing domain [143] 
IV Immunoglobulin repeats 
Bioactive, domain IV peptides 
[148, 165, 166] 
V Endorepellin anti angiogenic protein, 85 kDa domain V fragment  [144, 167, 168] 
 
  Therapeutic Applications of Recombinant Domains of Perlecan  
Domain Application Ref 
 
 
 
 
I 
(i) delivery of recombinant human BMP-2 for bone regeneration 
(ii) mediates cartilage repair through BMP2 delivery in a murine model of early OA 
(iii) enhanced VEGF165 activity/receptor phosphorylation in human bone marrow 
endothelial cells 
(iv) domain I-conjugated, HA hydrogel, chondrogenic  differentiation via BMP-2  
(v) electrospun collagen/gelatin fibers coated with domain I  increases GF binding 
(vi) chondrogenic differentiation on perlecan domain-I/Coll II/BMP-2 matrices. 
(vii) human perlecan domain I recombinant HSPG with 20-kDa GAG chains 
(viii) human perlecan domains I & II synthesized by baculovirus-infected insect cells 
[146, 152, 
154] 
[152] 
[153] 
 
[151] 
[169] 
[155] 
[170] 
[171] 
 
II 
(i) characterization of recombinant domain II 
(ii) human perlecan domains I and II synthesized by baculovirus-infected insect cells 
[172] 
[171] 
 
 
III 
(i) high-affinity nidogen-1 interactions with immunoglobulin-like domain 3 of perlecan 
(ii) cell-adhesive properties of three recombinant peptide fragments of domain III 
(iii) Ab mapping/tissue localization of globular cysteine-rich regions of domain  III. 
(iv) characterisation of rh domain III-3 containing a globular domain EGF-like motif 
[173] 
[174] 
[175] 
[145] 
 
 
IV 
(i) electrospun PCL-domain  IV peptide scaffolds, 3D pharmacokinetic cancer model 
(ii) stimulation of salivary gland cell assembly in-vitro by domain IV peptide 
(iii) novel domain IV peptide supporting cell adhesion, spreading and FAK activation 
(iv) chondrogenic activity of perlecan mapped to N-terminal domain I 
(v) rh domain IV-nidogen, laminin-nidogen, fibronectin, fibulin-2 and heparin binding. 
[176] 
[177] 
[148] 
[147] 
[165] 
 
 
 
 
 
 
 
 
V 
(i) domain V-silk biomaterial modulates endothelial cell-platelet interaction 
(ii) vascular proteoglycan 
(iii) inhibition of amyloid-β activation of α2β1 Integrin-mediated neurotoxicity  
(iv) treatment of vascular dementia 
(v) treatment of post-ischemic cerebral angiogenesis 
(vi) neuroprotective agent giving functional improvement in photothrombotic stroke 
(vii) inhibits amyloid-β induced brain endothelial cell toxicity restoring angiogenesis  
(viii) stroke therapy 
(ix) induction of VEGF in brain endothelial cells integrin α5β1 and ERK signaling  
(x) upregulated in  human brain arteriovenous malformation mediating VEGF effects 
(xi) modulates astrogliosis in-vitro and focal cerebral ischemia mediated through 
multiple receptors and increased nerve growth factor release 
(xii) neuroprotective and proangiogenic following ischemic stroke 
(xiii) endorepellin peptide anti-angiogenic module of domain V angiostatic module, 
antagonises α2β1 integrin and VEGFR2 interactions 
(xiv) inhibits α2 integrin-mediated amyloid-β neurotoxicity 
domain V β1 integrin-mediated cell adhesion, HS, nidogen and fibulin-2  binding  
[178] 
[179] 
[158] 
[161] 
[160] 
[180] 
[157] 
[159] 
[144] 
[181] 
[182] 
 
[156] 
[168] 
 
[183] 
[184] 
 
3.3.1 The stability of native proteoglycans in tissues.  
 Perlecan and the lectican PG family, and aggrecan in particular, are highly susceptible 
to proteolytic degradation in tissues (Figure 2c, Figure 3a, Table 3). A large number of 
cleavage sites have also been determined for perlecan [185] but the catabolism of this PG has 
not been as extensively investigated as that of aggrecan. Cleavage sites on the aggrecan core 
protein have been determined for ADAMTS-4 and ADAMTS-5, the so called aggrecanases, 
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and ADAMTS-1 and other ADAMTS family members as well as a number of matrix 
metalloproteases (MMPs) [186] (Figure 3c). Several serine proteases (tryptase, chymase, 
leucocyte elastase, cathepsin G) released when mast and other immune cells degranulate at 
sites of inflammation are also capable of degrading aggrecan directly [187] or by activating 
metalloprotease degradative enzymes [188]. The neutral protease calpain-m [189], and the 
lysosomal cysteine proteases cathepsin B, D, L, K, S [190] can also degrade aggrecan. 
 Table 3 MMP & ADAMTS-4, 5 cleavage sites in the aggrecan core protein 
                 Protease cleavage sites 
MMP Cleavages      
1. PEN360 361FFG 
2. VEE698 699WIV 
3. VGD952 953LSG 
4. VED1028 1029SGL 
5. VEE1295 1295ISG 
6. VEE1332 1333ISG 
7. VED1409 1410LSR 
8. AED1470 1471LSG 
9. PAE2166 2167THL 
ADAMTS-4,5 cleavages 
10. EGE373 374ARG 
11. ELE1545 1546GRG 
12. EEE1714 1715GLG 
13. AQE1819 1820AGE 
14. SQE1871 1872LGQ 
 
 
3.3.2 The biological half-life and function of aggrecan in tissues.   
 In adult articular cartilage the chondrocytes have an inherently low metabolic activity 
and undergo cell division infrequently.  Synthesis of ECM components is also low but 
sufficient to replenish degraded ECM components and maintain the tissue in a state of 
functional homeostasis.  The majority of cartilage matrix molecules are present in this tissue 
for many years, aggrecan, the major cartilage PG has a half-life close to 25 years [191], while 
type II collagen has a half-life of >100 years [192].  The half-life of high buoyant density A1D1 
aggregatable aggrecan from the IVD isolated by CsCl isopycnic density gradient 
ultracentrifugation is estimated to be 5.5 years whereas low buoyant density A1D6 IVD PGs 
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(decorin, biglycan) have a half-life of 21.5 years [193] and IVD collagens have a half-life of 
between 95 and 215 years [194]. 
Figure 10. Summary of the different forms of GAG polymers which have been assembled for tissue engineering 
applications.  Schematic of CS chains (a) linked to a peptide backbone via their non-reducing (b) or reducing 
termini (c) or by intra-chain attachment (d) in a prospective neo-proteoglycan.  Biomimetic peptidoglycan neo-
aggrecan and neo-lubricin  (e) GAG derivatised hyaluronan co-polymer (e) BPG10 co-polymer aggrecan 
mimetic (f) protein-GAG conjugates (g), polymer GAG complexes (h) Nano-composite  (i) which have have all 
been used as proteoglycan mimetics.  
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 Aggrecan in mature cartilage is heavily substituted with ~100 CS and ~25-50 KS 
chains representing ~90% of the mass of aggrecan (Figure 3c) [29].  KS is concentrated in a 
KS-rich region adjacent to the CS1 and CS2 regions in all species but rodent which have 
truncated core proteins devoid of this KS-rich region [195].  Small KS chains are however 
found in the G1 and G2 globular domains of aggrecan and in the interglobular domain (IGD) 
in all species [196].  The role of these KS-rich domain GAG chains is not known, however KS 
chains in the G1, G2 have been shown to suppress a T cell-mediated response when G1 is 
used as an arthritogen in an inflammatory OA model  [197].  IGD KS potentiates 
aggrecanolysis within the IGD by aggrecanases [198] (Fig 3c). No deleterious effects have been 
observed in the performance or turnover of aggrecan in murine cartilage, there would 
therefore appear to be no absolute requirement for KS in aggrecan or in a neo-aggrecan 
mimetic.  The other members of the lectican PG family do not contain KS.  Aggrecan forms 
massive link protein stabilized ternary structures with HA in cartilage and with tenascin-R in 
neuro-protective PNNs in the CNS/PNS (Fig 3d-f).  Monoclonal antibody 1-B-5 detects an 
unsulfated stub epitope on the CS chains of aggrecan and has been used to immunolocalise 
PNN structures in neural tissues, other members of the lectican PG family which have also 
been found in PNNs  would also be identified by this antibody (Figure 3e, f).  PNNs are 
mesh-like structures, composed of a hierarchical assembly of ECM molecules which 
encapsulate neurons and regulate their plasticity however much has still to be learnt of such 
interactions in the PNN and how they regulate neurons [199].  Although the basic components 
in PNNs are similar, they are not identical in all regions of the brain and the precise 
composition of their components varies in different regions of the brain [200].  The high 
localization of GAGs in PNNs is neuro-protective, chelating bioreactive molecules such as 
free Fe2+ and Fe3+ ions protecting the neuron from oxidative stress through free radical 
generation in ferrous and ferric ion catalyzed reactions [201].  Brain tissue is rich in 
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polyunsaturated fatty acids and susceptible to lipid peroxidation. Fe2+/Fe3+ are important 
initiators of free radical generation in such peroxidation reactions [202]. 
 A number of strategies have been used to prepare bio-scaffolds containing neo-
aggrecan mimetic molecules.  Three dimensional scaffolds containing GAG mimetic 
nanofibres mimic the biochemical and mechanical properties of native cartilage [203].  A 
number of scaffolds supplemented with CS have been used to promote MSC differentiation 
into osteogenic, chondrogenic and neurogenic cell lineages to improve cartilage and neural 
repair (reviewed in [47]). 
 
3.3.3 Rationale for the use of CS but not KS chains in aggrecan mimetic neo-PGs.   
 When the structure of native aggrecan is examined in detail, the rationale for only 
using CS in the design of a neo-aggrecan becomes apparent. Despite the intensive 
investigation of aggrecan’s structure and function for over five decades, there are still gaps in 
our knowledge of this molecule. The water binding properties of aggrecan stem from the high 
negative fixed charge density provided by its CS side chains and their associated counter-ions 
and how these partition in cartilage as described by the Gibbs Donnan Equilibrium.  In Figure 
1c and Table 1 we have identified unresolved aspects of aggrecan’s structure mainly 
involving its KS chains.  This information provides a rational basis for the use of CS but not 
KS in neo-PG design. Rodent aggrecan is deficient in KS chains with no obvious impediment 
in the articulation of rodent joints. 
 
3.3.4 Production of biomimetic neo-aggrecan.   
 Several strategies have been used to prepare aggrecan mimetics (Figure 10a-i).  One 
method uses a polyacryloyl chloride backbone to attach CS chains.  In this BPG10 aggrecan 
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mimetic, 22 kDa CS chains are attached via reaction of a terminal primary amine on the CS 
with acyl chloride groups on the polymer backbone (Figure 10j) with unreacted acyl chloride 
hydrolysed to carboxyl groups contributing to the negative charge density of this polymer [204]. 
BPG10 is an aggrecan mimetic of dissimilar molecular dimensions to native aggrecan, but its 
CS side chains have a similar bristle-like arrangement around the core structure to native 
aggrecan and these display a similar high fixed negative charge density (Figure 3a, b).  
BPG10 has impressive water regain characteristics, displaying 50% greater water regain on a 
weight basis to native aggrecan or CS chains in isolation. Moreover, the backbone in BPG10 
is not susceptible to proteolytic degradation thus the biological half-life of this neo-aggrecan 
is superior to that of native aggrecan.  AFM confirms the bottle-brush type distributions of the 
CS chains (Figure 3 a, b) around the polyacryloyl chloride backbone and the relative size of 
this neo-aggrecan which is significantly smaller than that of native aggrecan (Figure 10j). 
In another approach a CS backbone has been subjected to periodate oxidation to introduce 
reactive aldehyde groups in glucuronic acid residues of the CS chain and these were reacted 
with an HA binding peptide (GAHWQFNALTVRGGGC)[205] (Figure 11a). This 
peptidoglycan aggrecan mimetic (mAGC) containing CS chains with attached  HA-binding 
peptides replicated the HA-binding properties of native aggrecan ensuring that GAG 
localization was maintained within the scaffold [205]. Furthermore, localization of mAGC in 
the scaffold also stimulated synthesis of type II collagen. AFM demonstrated that the attached 
peptide chains in mAGC assumed bottle-brush-type orientations on the CS-core structure 
similar to the CS chain arrangements in native aggrecan core protein [204].  mAGC had 
superior water regain properties to that of native aggrecan and mAGC constructs had superior 
compressive strength (78% increase), The catabolism of mAGC constructs  by MMP-13 and 
ADAMTS-5 [206, 207] was also reduced compared to in animal models of OA [206, 208].  A 
peptidoglycan lubricin-mimetic, mLUB15 has also been prepared by similar methodology to 
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that of mAGC using HA binding peptide (GAHWQFNALTVRGGGC) and a type II collagen 
binding peptide (WYRGRL) attached to the CS backbone [209] (Figure 11b).  
 
Figure 11. Aggrecan, mAGC (a) and lubricin, mLUB15 (b) biomimetic neo-proteoglycans.  The native 
structure of lubricin is shown in (c).  See Fig 2 for the native structural organization of aggrecan. Reaction steps 
in the production of peptidoglycan mimetic neo-PGs (d). Periodate oxidation of GlcA in CS produces reactive 
aldehyde groups (21 aldehyde groups per CS chain).  HA binding peptide GAHWQFNALTVRGGGC or type 
II Collagen binding peptide WYRGRL are attached to the reactive aldehydes using the heterobifunctional 
crosslinker N-[b-maleimidopropionic acid] hydrazide (Trifluoroacetic salt) (BMPH).  In mAGC only the HA 
binding peptide is attached to the CS chain (a).  This product has a molecular weight of 40 kDa.  Production of 
the lubricin biomimetic mLUB 15 involves attachment of HA binding peptide and the type II collagen binding 
peptide (b).  5 mole HABP and 10 mole type II binding peptide are attached per mole of CS. 
 
5	mole	HABP	pepDde	
10	mole	COLL	II	BP	
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mLUB15	
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mLUB15 prevented pathological age-related effects on bovine vitreous, and enzymatically-
induced degradation [210].  A further GAG copolymer mimetic aggrecan has been developed 
using HA as a support backbone to which CS or heparin chains were attached using a 
hydrazide bi-functional reagent [211] (Figure 10i).  In yet another approach, collagen has been 
used as a backbone structure and CS chains attached by reaction of the CS chains with the e-
amino groups of lysine and hydroxylysine residues on the collagen by reductive amination 
using cyanoborohydride to produce a collaggrecan aggrecan mimetic [212] (Figure 12).  Lee et 
al [213] used ring-opening metathesis polymerization (ROMP) methodology to attach CS 
chains to microarray and surface plasmon resonance platforms for the assessment of CS 
mediated interactions with growth factors and binding proteins.  This methodology could also 
be used to produce alternative forms of aggrecan-mimetic molecules [213].   
3,3,5 Features of peptidoglycan neo-aggrecan and lubricin mimetic PGs.   
 In the production of mAGC, 16 amino acid HA-binding peptides 
(GAHWQFNALTVRGGGC) are attached to the CS backbone (Figure 11a) using periodate 
oxidation to produce reactive aldehyde groups in the CS chain (21 aldehyde groups per CS 
chain) and these are reacted with HA-binding peptide using the hetero-bifunctional cross-
linker N-[b-maleimidopropionic acid] hydrazide  to attach ten HA-binding peptides per CS 
chain.  Periodate (NaIO4) oxidation cleaves between the C2 and C3 vicinal diols in GlcA to 
form reactive aldehydes to attach CS to peptides or some other primary amine using a bi-
functional reagent.  Ring opening by periodate oxidation also forms highly flexible ‘hinges’ in 
an otherwise inflexible CS chain altering its physical properties and is permissive of the 
exploration of a more extensive range of conformational orientations than the native CS chain 
[214].   
 CS is a linear chain of 100-200 β1-3 and β1-4 linked D-GlcA residues attached to D-
GalNAc.  In order to accommodate the bulky space-filling sulfate groups, CS adopts a helical 
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structure [215].  X-ray fibre diffraction studies show that like HA, CS adopts a left-handed 3 
fold helix with sulfate groups pointing outwards towards the periphery of the helix where they 
interact with a surrounding cation and a water molecule [216]. The swapping of Na+ for Ca2+ 
changes the pitch of the helix from a 3 fold to a more compact 2 fold form. Opening of the 
GlcA ring structure by periodate oxidation introduces two aldehyde functionalities which are 
reactive with bi-functional reagents and these can be used to attach peptides to the CS 
backbone.  AFM confirmed that the attached peptides adopted a bristle-like distribution in a 
bottle-brush type arrangement on the CS core and they thus explored all available spatial 
orientations which would be expected to optimize the space-filling and interactive properties 
of the peptidoglycans [45]. mLUB15 is a biomimetic peptidoglycan lubricin prepared  using 
HA binding and type II collagen binding peptides  [209] .  This neo-lubricin has a dissimilar 
structure to that of native lubricin (Figure 11b) but its surface lubricative properties in 
articular cartilage provided efficient joint lubrication and it also had an increased resistance to 
proteolysis compared to native lubricin. The attached interactive binding peptides on 
mLUB15 equip it with interactive properties with synovial fluid components which promote 
boundary lubrication[217]. mLUB15 displayed synergistic properties with fibronectin [218], its 
interactive properties provided by the HA and type II collagen binding peptides ensure 
consistent mLUB15 localisation in squeeze films at the articular surface even under high 
pressure conditions. 
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Figure 12. Preparation of the neo-PG collaggrecan (a) by attachment of CS chains to the epsilon amino groups 
of lysine or hydroxylysine (ε-Lys, ε-Hydroxyls)  (b) on a collagen chain through the CS reducing terminus (c) 
using reductive amination and sodium cyano borohydride (NaBH3CN) (d).  Ring opening of the reducing 
terminal glucuronic acid residue produces a tautomeric reactive aldehyde which reacts with the e-amino Lys as 
shown by reaction with the reducing agent NaBH3CN in a reductive amination step.  
 
3.3.6 Tissue protective properties of neo-PGs.   
 While the specific design features of neo-PGs may make them resistant to degradation 
by proteases, the high charge density provided by their GAG components may provide an 
added bonus by enhancing the properties of naturally occurring protease inhibitory proteins 
within tissue repair environments.  Binding of GAGs to members of the plasma Serpin 
protease inhibitor family can significantly enhance their inhibitory properties [219]. GAGs 
enhance the inhibition of some of the coagulation cascade proteases including thrombin, 
factor Xa and plasmin [220].  Charge density appears to be an important requirement for 
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protease inhibitory activity [221].  Cell surface GAGs have also been reported to enhance the 
inhibitory properties of AT-III and tissue factor protease inhibitor displayed against VIIa [222].  
GAGs also modulate the activity and activation of the lysosomal exopeptidase tripeptidyl-
peptidase-I thus may affect the processing of peptide hormones and growth factors in-situ and 
tissue repair [122].  The protective effect reported for some neo-PGs over ECM components 
could potentially therefore, be exerted by effects on resident protease inhibitory proteins in 
tissues [22].  Interactions between GAGs and TIMP-3 suggest that this may improve TIMP-3 
inhibitory properties against MMPs and be protective in repair environments [55, 223]. TIMP-3 
is the only TIMP which has interactive properties with ECM components which localise it in 
tissues.  High molecular weight and cross-linked HA preparations such as hylan either down-
regulate the production of cartilage degrading MMPs or actively inhibit these enzymes in 
tissues thus they have beneficial chondroprotective properties [135].  These points are covered 
further in Table  4. 
 
3.3.7 Application of nano-delivery systems employing stimulatory peptides, GAGs and 
MSCs in cartilage repair strategies.   
 As already mentioned, CS has been applied in conventional scaffold systems for the 
stimulation and differentiation of MSCs, promotion of chondrogenesis and application in 
cartilage engineering (reviewed in [47]). CS (or heparin) nano-delivery systems and MSC or 
chondroprogenitor stimulatory peptides are also promising strategies in articular cartilage 
repair (Figure 8f).  Enzymatic treatments to release these bioactive peptides from the scaffold, 
increases their bio-availability, representing a novel methodological advance [224, 225]. 
Encapsulation of MSCs within collagen microparticles induces chondrogenic differentiation 
and the cartilaginous matrix elaborated within these micro-particles can be readily bio-
integrated into cartilage defects [226]. Triple helical collagen mimetic GPC(GPP)5-GFOGER-
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(GPP)5GPC-NH2  and fibronectin RGD cell attachment peptides incorporated into degradable 
and non-degradable polyethylene glycol gels  have been examined for their ability to promote 
cartilage repair through the  promotion of chondrogenic differentiation of MSCs. Interestingly, 
the collagen mimetic peptide provided superior results in cartilage repair than the fibronectin 
peptide [224, 227].  Pre-chondrogenic cells cultured on bioactive self-assembled peptide nano-
fibres undergo elevated growth and chondrogenic differentiation thus this substrate is 
appropriate for further assessment in cartilage regeneration strategies [228]. 
 
 HA derivatised with CS (or heparin) using hydrazide bifunctional reagents and 
reductive amination [229] is a highly flexible methodology in terms of the density of CS (or 
heparin) which can be achieved and is also suitable for the generation of nanoparticles.  CS-
HA and heparin-HA conjugates both promote cartilage repair, however heparin-HA is more 
effective as an FGF-2 delivery system. Aggrecan-mimetic GAG nanoparticles stabilize and 
optimize FGF-2 delivery for repair applications [117].  Cellulose based-CS mimetic scaffolds 
also display positive traits in cultures of MSCs in articular cartilage repair [230].  Recent 
advances with artificially sulfated polysaccharides to improve cell growth and differentiation 
and drug delivery also show promise in tissue engineering applications [231]. Biphasic semi-
interpenetrating polymer network hydrogels impregnated with CS nanoparticles, (Zein 
nanoparticles, ∼150nm) interspersed in a calcium cross-linked alginate-PVA blend, have an 
interconnected porous microstructure conducive to cartilage repair.  Primary chondrocytes 
loaded into these hydrogels exhibit high expression levels of sox9, aggrecan and type II 
collagen but low expression of type I collagen and this hydrogel is considered a useful 
mimetic for repair of irregularly shaped cartilage defects [118]. NP cells cultured on laminin 
peptides and surface conjugated α3 integrin receptor peptides P4 and P678, and the α2, α5, α6, 
β1 integrin recognizing peptide AG10 on polyacrylamide matrices showed elevated 
  
43 
 
expression of aggrecan, N-cadherin, and types I and II collagen.  Integration of the neo-tissue 
with existing NP tissue suggested that this methodology promoted NP cell vitality conducive 
to repair or regeneration of the IVD [232]. RGDS functionalized Streptococcal collagen-like 
(SCL) mimetic hydrogels have been developed for MSC stimulation to promote articular 
cartilage repair [225]. An SCL protein modified with GAG-binding peptides was processed into 
a hydrogel format containing a RGDS peptide which could be released by treatment of the 
hydrogel with MMP-7.  MSCs cultured in this hydrogel expressed a 3.9 fold increase in 
COLAII, 7.6 fold increase in Acan and 5.6 fold increase in Sox9, and significantly elevated 
levels of aggrecan and type II collagen synthesis at the protein level. Temporal activation of 
embedded stimulatory biomimetic peptides in hydrogels therefore represents a particularly 
innovative approach to cartilage repair.  Recent studies have also demonstrated the usefulness 
of aldehyde-modified ECM proteins for targeted adherence to biological tissue surfaces. 
Aldehyde-modified lubricin displays enhanced binding to PRG4-depleted articular cartilage 
and has been used for cartilage resurfacing and is a convenient method for overcoming loss of 
lubrication during the early stages of OA [137]. Collagen fibrils have also been embedded in a 
network of photo‐cross-linked acrylated HA, CS, or sulfated HA (sHA) 3D hydrogels [233].  
Endothelial cell proliferation was significantly increased in sHA gels compared to CS-
derivatised or non-derivatised HA hydrogels.  Sulphation of HA increases the hydrogels 
growth factor binding capacity, and reduce its susceptibility to degradation by hyaluronidases 
[114].  Sulfated HA hydrogels are also suitable as carriers for hMSCs, promote chondrogenesis, 
inhibit hypertrophy and have been used in intra-articular injections to delay/reverse OA 
changes in joint tissues [114]. sHA micro-particles have been prepared for the controlled 
delivery of growth factors including BMP-2 and TGF-β1 [119, 234]. HA micro-particles 
containing heparin have also been used for the delivery of BMP-2 [235]. An HABP-PEG-
collagen-binding peptide co-polymer  (HABP2-8-arm PEG-COLBP) has been used to 
immobilise HA in cartilage and to improve surface lubrication to protect the articular surface 
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from abrasive damage [236]. Quartz crystal microbalance - isothermal calorimetry has 
demonstrated this polymer effectively reduced the progression of post-traumatic OA [236]. 
High molecular weight HA also protects articular cartilage by inhibiting aggrecanase 
expression by the resident chondrocyte cell populations [135].   
 
4. Protection of the articular cartilage surface from abrasion and preservation of its 
lubricative properties  
 The surface of articular cartilage is a key component of the articulating joint structure 
and is the region where articular lesions first appear in OA arising from surface abrasions 
which occur due to overloading of this surface tissue (Figure 13).  These lesions continue to 
develop with the progression of OA eventually leading to full depth defects down to the 
calcified cartilage and bone by a process known as eburnation.  OA represents a large and 
rapidly increasing global disease burden challenging health-care systems worldwide. Disease 
progression in OA results in increasing pain and loss of joint function, it is at early 
symptomatic stages that OA treatment is more likely to be successful. Treatment of end stage 
OA lesions have so far met with little success despite a concerted global anti-arthritic program 
spanning five decades. With changing global ageing trends OA prone individuals >65 years of 
age will be prominently represented in the general population. This will result in OA 
becoming a leading musculoskeletal condition by 2040 and in the USA it is estimated that 
78.4 million individuals will suffer from OA [Arthritis Foundation. Arthritis By the Numbers 
/ Book of Trusted Facts & Figures. 2018; v2; 4100.17.10445  arthritis.org].  The incidence of 
OA has already doubled since the mid 20th century [25].  
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Figure 13. Morphological features of 55 year old male donor knees (a, b).Toluidine blue stained vertical sections 
of weight bearing regions of femoral condyle articular cartilage  normal (c) and mildly abraded (d) from the 
areas depicted in (a) and (b) showing less intense staining and reduced cartilage thickness in the abraded 
specimen. Arrows depict the articular surface, M, medial; L, lateral compartment.  The left knee is non-
degenerate while the right knee shows very early stages of OA with areas of surface damage in the weight 
bearing region of the condyle.  Clinically this is the type of cartilage recommended for treatment using 
viscosupplements, without such a preventative approach the indicated abraded areas will expand into full depth 
lesions severely impacting on joint function.  
 
As already shown, images of bovine articular cartilage demonstrate that type I collagen, 
versican and lubricin/PRG4 are prominent components of the articular surface (Figure 7-9).  
Type-I collagen counters the tensional shear forces generated during joint articulation. 
Versican, is an HA binding PG and may contribute to the retention of HA at the articular 
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surface.  Lubricin/PRG4 is a mucin glycoprotein/PG produced by surface zone synoviocyte-
like cells of a flattened morphology and is deposited as a fine deposit at the articular surface.  
Lubricin as its name indicates has roles in the lubrication of the surface of articular cartilage.  
The major space-filling hydrodynamic PG of articular cartilage is aggrecan which is 
distributed throughout this tissue.  Aggrecan equips cartilage with its ability to withstand 
compressive load.  A schematic  already presented shows the organization of these articular 
components (Figure 1).  Type VI and XI collagen have also been shown to provide cell-
pericellular interconnections which may contribute to cell ECM communication (Figure 2).  
HA conveys many beneficial properties to the structural integrity and function of synovial 
joints.  Through its interaction with aggrecan, it serves as a hydrodynamic space filler in 
articular cartilage protecting resident chondrocyte cell populations from the significant weight 
bearing and shear forces they experience in the joint [115].  HA is also a major component of 
the synovial fluid that bathes and lubricates the articular joint surfaces along with lubricin 
ensuring smooth low frictional movement during normal day to day joint articulation.  A 
comparison of the boundary lubrication properties of two batches of HA, including high 
molecular weight Healon® failed to provide as efficient joint lubrication as lubricin [237].  A 
synthetic lubricin neo-PG, mLUB also provided efficient lubrication of the surface of 
cartilage and acted in a protective capacity preventing the generation of surface lesions typical 
of those that occur in the development of OA [209].   
 
4.1 Synovial fluid HA.   
 The average half-life of synovial fluid high molecular weight HA of 6 x 106 Da is 
13.2h in rabbits while a smaller HA of molecular weight 9 x 104 Da had a half-life of 10.2 h.  
Steady state values for synovial HA in rabbits and sheep are reported to be 0.5-1 day [238].   
Native synovial HA is a thixotropic non-Newtonian viscoelastic solution whose viscosity is 
shear dependent [239-245]. At high shear the viscosity of HA gels may drop by as much as 
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∼103 times and it then obeys as a Newtonian fluid [240]. The elasticity of HA increases with 
increasing molecular weight and concentration of the HA molecular network. These 
rheological properties of HA are important in the lubrication of joints  [239]. Commercial 
preparations of HA of variable sizes are available (Table 5).  These differ in their rheological 
characteristics in-vitro and the properties they convey to synovial fluid and joint-lubrication 
in-vivo [241-245]. 
 Synovial fluid HA in normal healthy knees has a molecular weight of 7 x 106 Daltons  
whereas HA in the OA or RA knee HA has a molecular weight of 4.8-5.0 x 106 Daltons [246].  
HA in the OA knee has a broad polydisperse size distribution with a weight average 
molecular weight of 1.2-4.5 x 106 whereas the HA from a normal joint has a weight average 
molecular weight of 1.6-10.9 x 106 Da [115, 247, 248]. The concentration of HA in the OA or RA 
knee (1.09-1.20 g/l) is lower than in the normal healthy knee (1.45-3.12 g/ml) and is a smaller 
size range [246, 247, 249] thus the rationale for the use of HA in visco-supplementation procedures 
is to replenish these deficient HA levels to recover normal knee-joint function. 
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Figure 14. Stem cell niches delineated at their margins by the  immunolocalization of perlecan in the surface 
regions of second trimester human foetal knee (a, b) and hip (d, e, f) articular cartilage using anti-perlecan 
domain IV antibody A7L6.  The boxed region in e is provided at higher magnification in segment f. Type I 
collagen is also a prominent component of human foetal articular cartilages, type I collagen is immunolocalised 
in a foetal hip joint in photosegment c. Scale bars 100 µm.  Images reproduced from [250] [doi: 10.24966/SRDT-
2060/100009] with permission.  Images copyright J. Melrose 2014. 
 
4.2  HA and visco-supplementation.   
 A number of purified HA preparations have been developed for visco-supplementation 
(Table 4).  HA preparations, can be broadly categorized into (i) HAs (unmodified HA) and (ii) 
cross-linked HAs (Hylans). Standard HAs are low to medium molecular weight HA fractions 
extracted from rooster combs or bovine vitreous[251, 252].  Hylans are chemically cross-linked 
high molecular weight, HA derivatives. Hylan G-F 20 (Synvisc® , Genzyme), consists of two 
hylan polymers, hylan A and hylan B[253]. Hylan A extracted from rooster combs is pre-
treated with formaldehyde resulting in cross-link formation between hydroxyl groups on the 
HA and amino/imino group of proteins between 2 and 8 native HA chains are thus cross-
linked in hylan preparations producing an HA product of ~ 6 MDa [253, 254]. The average 
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protein content of hylan A is 0.4–0.8% [255].  Hylan B is formed by further cross-linking of 
hylan A using divinyl sulfone [251] to form a visc-oelastic gel [253, 254] with ~20% divinyl 
sulfone crosslinks. NASHA (non-animal stabilized HA) was subsequently developed to 
provide a high molecular weight cross-link stabilized HA preparation from a bacterial ferment  
to avoid any immunological sensitivity issues which have been reported for animal sourced 
HAs [256]. NASHA are new-generation HAs with improved biophysical properties compared 
to unmodified HA.  NASHA injections deliver an increased density of HA and display a high 
resistance to intra-articular degradation increasing its intra-articular residency time and 
clinical effect.  NASHA was designed to deliver a single injection of high density 
intraarticular HA sufficient for it to be an effective visco-supplement. Despite the small extent 
of molecular cross-linking in NASHA, the stabilization provided has a major effect on the 
rheologic properties of NASHA, and is a key aspect of its functional properties as a lubricant 
and shock-absorber within the knee joint. NASHA has greater elasticity and viscosity, 
compared to existing commercial HA preparations, and outperforms endogenous HA 
synthesized by young, healthy joints.  Q-Med AB originally developed Durolane® for 
ophthalmic applications but it also had application as a visco-supplement [257]. Q-Med AB 
manufactures all of the formulations of NASHAs including Durolane® and Restylane ®. 
NASHA is stabilized using 1, 4-butanediol diglycidyl ether, this cross-linking reagent reacts 
with the hydroxyl groups of the repeat disaccharide unit.  Cross-linking conditions are 
carefully controlled to ensure that only ~0.5-1.0%  of the residues are modified.  This 
represents ~ 1 residue  in every 100 disaccharide units linking two native HA molecules 
together and while it changes the physical properties of the HA forming a 3D network the 
majority of the functional groups are unmodified and available to undertake interactions 
which normally occur with the native HA molecules.  Each HA gel microbead thus formed is 
effectively a single HA molecule however it has a massively increased molecular weight 
increased by a factor of around ten thousand billion ie 1013 [256]. This size imparts important 
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beneficial therapeutic properties to NASHA in terms of its rheological and visco-elastic  
performance as a visco-supplement and increases its residence time in the intra-articular space.  
Furthermore, NASHA is less susceptible to depolymerisation by free radicals which further 
increases its biological half-life in the knee-joint. Treatment with NASHA is by a single 
injection of 60mg (209) which ensures a rapid response to pain alleviation in the OA knee and 
further advantages in its clinical management  over protocols which require multiple (up to 
five) injections of HA to produce the same pain alleviation effect. 
	
																								Table	4.	HAs	used	for	visco-supplementation	procedures	for	the	treatment	of	OA	
Mw	(Da)	 HA	 Manufacturer	 Ref	
0.5-1	x	106	 Hyalgan®	
Suplasyn®	
Fermathron®	
Fidia	Pharma	USA	Inc	
Rubio	Laboratories	
MegaChem,	Berlin	GmbH	
[243,	 258-
260]	
0.8-1.5	x	106	 Go-on	Matrix	 Rottapharm|Madaus,	Monza,	Italy	 [261]	
1.1	X	106	 Gelsyn-3	 IBSA Farmaceutici Italy	 [262]	
1-1.8	x	106	 Ostenil®	
Orthovisc®	
Viscoseal®	
TRKB	Chememdica,	UK	
DePuys	Synthes	
TRKB	Chememdica,	UK	
	
	
[243,	 258,	
259]	
1.5-2.0	x	106	 HyalOne®/Halubrix®	
Gel-one®	cross-linked	HA	
Zimmer-Biomet	
	
Rottapharm|Madaus,	Monza,	Italy	
[263]	
[244]	
1.0-2.9	x	106	 Monovisc®	 DePuy	Synthes	Mitek	Sports	Medicine	 [243]	
2.4-3.6	x	106	 Euflexxa®	
Synocrom	Forte	
Ferring	Pharmaceuticals	 [259,	264]	
6	x	106	 Synvisc	(Hylan	G-F	20)®	
Synvic	One	(Hylan	G-F	20)®	
Sanofi	(USA)	 [259,	265]	
6.2-11.7	x	106	 Supartz®	
Supartz	FX®	
BioVentus	,	USA	 [243,	 258,	
259,	266]	
HMW	but	weight	not	
provided	
Hymovis,	HYADD	4		
High	molecular	weight		
viscoelastic	HA.			
Fidia	Pharma	USA	Inc	 [267]	
2.5-3	x	106	 Viscoplus_Matrix®,	
Viscoplus_Gel®,	
Biomedical	B	Baumann	Group	 [241]	
10	x	1012	Da	 NASHA	HAs	
Durolane®	
	
Bioventus	(USA)	
[242,	 256,	
268,	269]	
 
4.3 HA for reconstructive surgery and cosmetic applications.   
 Several HA formulations have been developed specifically for applications in 
cosmetic [270] and ophthalmic corrective surgical applications (Table 5).  HA ophthalmic visco-
elastic devices are used in vitro-retinal, anterior segment and glaucoma surgery, and corneal 
transplantation procedures in the eye and on its surface to prevent dehydration and to 
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promote wound healing [271]. Dermal filling with cross-linked HA such as Princess® Filler is a 
viable treatment option for the correction of various soft tissue defects of the face resulting 
facial lipoatrophy, morphological asymmetry of the face, or debilitating depressed scars [272]. 
The space-filling and hydrating properties of HA preparations [273] are important attributes in 
cosmetic and restorative applications[270, 274].  The longer residence time due to improved 
stability of high molecular weight cross-linked HAs such as Restyllane  are also important 
performance indicators.  Non-stabilised HA has a relatively short half-life in tissues and is 
susceptible to depolymerisation by free radicals generated during inflammation.  The 
resultant small molecular weight oligosaccharide products have angiogenic properties and 
also stimulate many cell types leading to synthesisis and activatation of MMPs leading to 
unwanted ECM remodeling.  Some of the HAs used in cosmetic and reconstructive surgery 
have similar properties to the HAs used for visco-supplementation of synovial joints  and are 
made by the same manufacturer eg Restyllane® and Durolane® NASHA. Many HA 
formulations for dermal injection have additives such as sorbitol or mannitol anti-oxidants and 
local anaesthetics (lidocaine) to ease extended injections.   
Table	5.	FDA	Approved	Hyaluronan	Dermal	Fillers	for	Cosmetic	and	Reconstructive	Procedures	
HA	Product	 Manufacturer	 Application	
	1.					Revanesse	Versa	
	2.					Revanesse	Versa	+				
										Lidocaine	
Prollenium		
Medical		Tech	
Inc,Aurora,USA.	
	
mid	to	deep	dermal	injection	to	correct	facial	wrinkles/folds	[275]	
1. Restylane	Lyft						
	2.				Restylane	Refyne,		
	3.				Restylane	Defyne	
Q-Med	AB,		
Uppsala,		
Sweden	
Dermal	implantation	for	aesthetic	use	in	the	hands		
mid-deep	dermal	 injection	for	aesthetic	correction	of	moderate	
to	severe	facial	wrinkles	and	folds	in	adults	>21	years	old	[276]	
1. Juvederm	Volbella	XC	
2. Juvederm	Vollure	XC	
3. Juvederm	Violift®	
	4.						Juvederm	Voluma®	
	
	
	
Allergan	Inc,		
Dublin,	Ireland.	
dermal	injection,	correction	of	facial	wrinkles	and	folds		
licenced	in	USA	for	lip	injection/lip	augmentation	and	correction	
of	perioral	rhytids	in	adults	>21	years	old	[277].	
cross-linked	 	 90%	 LMW	 HA	 and	 10%	 HMW	 HA	 	 giving	 better	
filling	qualities	than	HMW	HA	fillers	[278].	
Princess®	Dermal	filler	 Croma-Pharma	
GmbH,		
Treatment	 of	 facial	 lipoatrophy,	 morphological	 asymmetry,	 or	
debilitating	scars	[272].	
Cohesive	 polydensified	
matrix	HA		volumizer	
	(CPM-HA)	
Belotero-
Balance,			
Geneva,	Suisse	
Cheek	augmentation,	aesthetic	improvement	of	nasolabial	folds	
[279]	 and	 Etched-In	 Fine	 Facial	 Lines	 [280].	 Augmentation	 with	
lidocaine,	epinephrine.	
1. Stylage	S	cross-linked	
HA	
	
2. Stylage	Hydromax	
	
3. Stylage	L,	Stylage	XL	
	
	
4.	Stylage	Special	Lips	
Vivacy	Labs,	
	France	
(i)	 Cross-linked	 HA	 inter	 penetrating	 network	 gel+	 lidocaine	 +	
Mannitol;	for	the	correction	of	superficial	lines	and	wrinkles	[281].	
(ii)	transdermal	injection/rehydration	of	dehydrated	skin	[282].	
(iii)	treatment	superficial	wrinkles,	crow’s	feet,	frown	lines,	fine	
cheek	perioral	wrinkles,	oral	commissures,	dark	eye	circles	[282].	
(iv)	dermal	injection	of	very	deep	wrinkles/naso-labial	folds	
(v)	 dermal/subcutaneous	 deep	 injection	 to	 treat	 facial	 volume	
defects,	restore	facial	contours,	augment	cheekbone	area	[282].	
(iv)	superficial/mid	dermal	injection,	augment	lip	volume	
Surgiderm		facial	fillers	 Allergan		 HMW	cross-linked	HA	hydrogel	dermal	filler.	
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Surgiderm®	24XP,		
Surgiderm	30XP.			
Irvine,		
CA,	USA	
Surgiderm	 24XP	 used	 to	 treat	 medium	 to	 deep	 lines/wrinkles	
Surgiderm	30XP	treats	mid-deep	dermis		[242,	283].	
 
4.4 The efficacy of high or low molecular weight HA in OA therapeutics.   
 The size of HA in the external environment may influence the synthesis of HA by 
resident synovial fibroblasts in the knee joint [284-286] with HA sized 0.5 x 106 Da stimulating 
endogenous HA synthesis but not higher Mw HA [287]. HAs within the molecular weight range 
of 0.5 -1.0 x 106 Da partially restore rheological properties of synovial fluids and synovial 
fibroblast metabolism in animal models [284].  High molecular weight HA of 2 x 106 Da 
inhibits arachidonic acid release by synoviocytes in-vitro but lower molecular weight forms of 
HA do not.  High molecular weight HA displays anti-inflammatory properties which coupled 
with its inhibition of arachidonic acid release contribute to a beneficial clinical and pain relief 
OA treatment profile [288] and it provides greater beneficial effects on PG synthesis and in the 
maintenance of visco-elastic joint lubrication [289, 290].  A comprehensive review [291] of 
MEDLINE, EMBASE, and PUBMED databases uncovered 2,782 articles on HAs used in OA 
treatment.  Of these, six major categories were identified to describe the beneficial effects 
afforded by treatment with high molecular weight HA preparations.  These were (i) 
chondroprotection [135, 241, 285, 289, 292, 293, 294, 295-297, 298-300] (ii) promotion of PG/GAG 
biosynthesis [287, 295, 297, 301, 302, 303], (iii) anti-inflammatory effects [285, 290, 293, 295, 303, 304], (iv) 
mechanical effects [296, 299, 302, 305], (v) effects on subchondral bone [294, 306]and (vi) analgesic 
properties [300, 307]. 
 
 The development of high molecular weight HAs such as Hylan G-F and Durolane 
represent significant technological advances in terms of their in-vitro rheological properties 
which translate in-vivo into improved visco-elastic, chondroprotective weight bearing 
properties and pain alleviation in the treatment of OA.  These forms of HA also have longer 
residence times in the knee-joint due to their resistance to de-polymerisation by free radicals 
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during the inflammatory conditions which occur in the OA joint thus they are active for 
prolonged periods protecting the cartilage surface from further damage.  Therapeutic visco-
supplementation procedures developed for Durolane and the Hylans use single injections, a 
significant  improvement over multiple injection protocols with associated adverse effects at 
injection sites.   
 
4.5 Augmented Visco-supplement HA formulations for the treatment of OA.   
 HA has been used in combination with steroids, NSAIDs, anti-oxidants, DMOADs, 
anaesthetics, and GAG additives in order to improve the clinical performance of these 
formulations in the treatment of OA.  These are summarized in Table 6. 
Table	6.	Augmented	HA	Viscosupplement	Formulations	used	for	the	Treatment	of	OA	
HA	 Mw	(kDa)	 Additive	 Property	 Ref	
HA	solution	 500-730	 Carprofen			
Triamcinolone		acetonide		
Dexamethasone			
Prednisolone				
NSAID	
Cortocosteroid	
Cortocosteroid	
Cortocosteroid	
[308]	
	
[309]	
HA	hydrogel	 n/a	 Dexamethasone			 Cortocosteroid	 [310]	
Adant	(Suprahyal)		 500-1000	 Tenoxicam			 NSAID	 [311]	
Variofill	 (Adoderm,	
Langenfeld,	Gmbh)	
HMWCR		 Diclofenac		
Sodium	clodronate			
Triamcinolone	acetonide	
Ropivacaine	HCl		
NSAID	
DMOAD	
Cortocosteroid	
Anaesthetic	
[312]	
	
[313]	
Hydros,	Hydros-TA	 HMW	 Triamcinolone	acetonide	 Cortocosteroid	 [314]	
Cingal	 1900	 Triamcinolone	acetonide		 Cortocosteroid	 [315]	
Hylan	GF-20	 HMWCR	 Triamcinolone	acetonide		 Cortocosteroid	 [316]	
HA	solution	 800	 Mannitol			 Anti-oxidant	 [317]	
Go-on	matrix	
Go-on	
Hanox-M	
Hanox-M-XL	
Hyal	G-F	
Synolis	V-A	
n/a	
800	
1000	
n/a	
1000	
2000	
Sorbitol	
Mannitol		
Mannitol		
Mannitol		
Mannitol		
Sorbitol				
Anti-oxidant	
Anti-oxidant	
Anti-oxidant	
Anti-oxidant	
Anti-oxidant	
Anti-oxidant	
[261]	
[318]	
[319]	
[318]	
[298]	
Ostenil	Plus	 1500	 Mannitol			 Anti-oxidant	 [320]	
Happyvix	 1500	 Mannitol		 Anti-oxidant	 [320]	
Happycross	 1500	 Mannitol		 Anti-oxidant	 [320]	
Synolis	V-A	 2000	 Sorbitol		 Anti-oxidant	 [320]	
HA	4AR	conjugate	 2200	 4	aminoresorcinol		 Anti-oxidant	 [321]	
Ostenil	 1000-2000	 L-glutathione			 Anti-oxidant	 [322]	
Arthrum	HCS	 2800	 CS			 GAG	 [320]	
Surgical	Syonium	 2800	 CS			 GAG	 [320]	
HA-sCT	conjugate	 200	 Salmon	calcitonin		 DMOAD	 [323]	
HA	ADAMTS	inhibitor		 n/a	 ADAMTS	inhibitor		 DMOAD	 [324]	
HA	hydrogel	 60-120	 Doxycycline		 DMOAD	 [296]	
Hanox	
	
Hanox	M-XL	
1500	
	
n/a	
Cortivazol			
Triamcinolone	hexacetonide		
Mannitol	+	lidocaine	clorhydrate		
Cortocosteroid	
Cortocosteroid	
Anti-oxidant	 +	 local	
anaesthetic	
	
[325]	
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n/a	not	available,	HMW	,	high	molecular	weight;	HMWCR,	high	molecular	weight	cross-linked.	
 
4.6 Versatility of conjugated HA as a delivery vehicle for therapeutic compounds.   
 HA is an extremely versatile carrier molecule which has been conjugated with drugs 
and bioactive compounds in hydrogel, micelle, nano-particle and liposome formulations for 
drug delivery with the amphiphilic properties of the HA adding to the delivery process.  The 
targeting of tumour cells has been intensely investigated [326, 327, 328] and some particularly 
innovative HA targeting systems have been developed [329] and improved methods of delivery 
of compounds to previously impenetrable deep target sites deep in tumor masses [330]. The 
ability of HA to target CD44 overexpressing tumor cells is a useful trait for the specific 
delivery of therapeutic compounds [328, 331] and has also been exploited in some novel imaging 
modalities for tumor cells [332].  Such approaches can also be utilized to target cells other than 
tumor cells, a thermo-responsive HA nanogel drug delivery system which targets 
macrophages has been developed [333]. The versatile properties of HA as a delivery vehicle for 
specific cell targeting and improved cellular uptake of compounds represents another facet of 
the biology of HA separate from its roles as a visco-supplement. The examples outlined in 
Tables 7 and 8 clearly demonstrate the versatility of HA as a delivery vehicle. A number of 
glyco-polymers with appropriate rheological properties and low cytotoxity have also been 
evaluated with a view to application in visco-supplementation procedures [245, 334].  
																									Table	7	Conjugation	of	HA	with	Bioactive	Compounds	as	a	Therapeutic	Delivery	Vehicle	
Attached	compound	 Conjugate	form	 Application	 Ref	
Methotrexate	 Coated	 magnetic	 polydopamine	
nanoparticles	
	
Optimized	 HA-methotrexate	
conjugates	
Multimodal	 Imaging-Guided	
Multistage	 Targeted	 Chemo-
Photothermal	Therapy	
OA	therapy	
[335]	
	
	
[336]	
Steroids	 Steroid	grafted	on	to	HA	 Antioxidant	delivery	 [337]	
EGF	 HA-EGF	conjugate	 Chronic	wound	healing	
Skin	wound	healing	and	regeneration	
[338]	
[339]	
Anti-tumor	 necrosis	
factor-α	
antitumor	 necrosis	 factor-α	 HA	
conjugate	
early	 healing	 effects	 in	 a	 rat	 burn	
model	
[340]	
Epigallocatechin-3-O-
Gallate	
HA-Epigallocatechin-3-O-Gallate	
Conjugates	injectable	hydrogel	
Free	Radical	Scavenging	 [341]	
Sonic	hedgehog	 Sonic	Hedgehog-HA	conjugates	
	
Multivalent	 Sonic	 Hedgehog	
conjugate	
Wound	healing	
	
Diabetic	Wound	Healing	
[342]	
	
[343]	
Catechin		 hyaluronic	 acid-green	 tea	 catechin	 Targeted	 intracellular	 protein	 [344]	
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nanogels	 delivery	
Quercetin	 HA-	quercetin	conjugated	micelles	 A	tumor	cell-targeted	prodrug	 [345]	
Opiods	 HA-opioid	conjugate	 Controlled	 delivery	 treatment	 for	
pain	alleviation	applications	
[346]	
	
Table	8.		The	versatility	of	HA	delivery	systems	for	anti-cancer	drugs	
Drug	 Conjugate	form	 Application	 Ref	
Adriamycin	 Adriamycin	pro-drug	HA	micelles	 targeted	drug	delivery	with	enhanced	
antitumor	efficacy	
[347]	
Tocopherol	succinate	 Redox-responsive	 	 disulphide	
stabilized	HA	-tocopherol	succinate	
micelles	
Melanoma	 [348]	
Mertansine	Toxin	 HA-Shelled	 Disulfide-Cross-Linked	
Nano	polymersomes			
Ultrahigh-Efficiency	 Reactive	
Encapsulation	 CD44-Targeted	
Delivery	
[349]	
curcumin	 and	
alendronate	
Multifunctional	 redox-responsive	
and	 CD44	 receptor	 targeting	
polymer-drug	nanomedicine	
targeted	drug	delivery	with	enhanced	
antitumor	efficacy	
[350]	
Iridium(III)	
Anticancer	Drugs	
Reduction-	 and	 pH-Sensitive	
Hyaluronan	Nanoparticles	
	
targeted	drug	delivery	with	enhanced	
antitumor	efficacy	
[351]	
Nimesulide	 Nimesulide-HA	conjugate	 Treatment	 of	 CD44-overexpressing	
HT-29	colorectal	cancer	
[352]	
5-fluorouracil	 Thermosensitive	 chitosan	 hydrogel	
containing	 	 5-fluorouracil	
nanoparticles	
Targeted	 controlled	 delivery	 of	 5-
fluorouracil	Transcorneal	tumours	
[353]	
Gold	 nanoclustered	
HA	
Gold-Nanoclustered	 HA	 Nano-
Assemblies	
Photothermally	 Maneuvered	
Photodynamic	Tumor	Ablation	
[354]	
HA	 oligosaccharide	
Ca	Phosphate			
hybrid	 HA	 oligosaccharide-Ca	
phosphate	nano	crystals	(Chrysalis)	
Dual	 pH/redox	 responsive	 and	 CD44	
receptor	targeting	
[355]	
Death	 Receptor-5	
Antibody	Conjugate	
HA	conjugate	 Targeted	 Treatment	 of	 Liver		
Metastasis	
[356]	
Lanthanum	HA-Pt	 Chemotherapeutic	HA-Pt	 Chemotherapeutic	 Agent	 HA-Pt	 to	
Track	In	Vivo	Distribution	of	HA-Pt		
[357]	
Silybin	 HA-glycyrrhetinic	acid	micelles	 Liver	targeted	hepato	protection	 [358]	
trastuzumab.	 HA-tyramine	 sustained	 release	
hydrogels		
HA-tyramine	 sustained	 release	
hydrogels	for	trastuzumab.	
[359]	
Doxorubicin	
	
	
	
	
	
Doxorubicin-
glycyrrhetenic	acid	
	
camptothecin-
doxorubicin	
Doxorubicin-cisplatin	
	
gemcitabine	 and	
doxorubicin	
Reversibly	 crosslinked	 hyaluronic	
acid	nanoparticles	
multiwalled	HA-carbon	nanotubes	
	
GE11	 peptide	 modified	 reduction-
responsive	HA	nanoparticles	
Doxorubicin	 self-assembled	 	 HA	
nano-particles	 conjugated	 with	
glycyrrhetinic	acid	
Combinatorial	HA	conjugate	
	
HA	 Doxorubicin-cisplatin	
conjugates	
sequential	 delivery	 of		
gemcitabine/doxorubicin	
doxorubicin	delivery	to	drug	resistant	
CD44+	human	breast	tumors	
targeted	 intracellular	 delivery	 of	
doxorubicin	into	cancer	cells	
High	 efficacy	 	 doxorubicin	 for	 breast	
carcinoma	
targeted	drug	delivery	with	enhanced	
antitumor	efficacy	
	
Synergistic	camptothecin-doxorubicin	
antitumor	dual	HA	conjugates	
Cellular	uptake	and	internalization	of	
Doxorubicin-cisplatin	
treatment	 of	 triple	 negative	 breast	
cancer	cells	
[360]	
	
[361]	
	
[362]	
	
[363]	
	
	
[364]	
	
[365]	
	
[366]	
Docetaxel	 Docetaxel-HA	conjugate	 CD44-targeted	 docetaxel	 conjugate	
for	cancer	cells	and	cancer	stem-cells	
[367]	
Camptothecin	 bifunctional	 HA	 camptothecin	
prodrug	
targeted	drug	delivery	with	enhanced	
antitumor	efficacy	
[368]	
Gemcitabine	 HA-coated	liposomes	 active	 targeting	 of	 gemcitabine	 to	
tumor	cells	
[326]	
	
	
	
	
	
	
redox	sensitive	vitamin	E	succinate	
paclitaxel-HA	nanoparticles		
paclitaxel	 C-6	 	 hexanediamine-
modified-HA-	
HA	 oligomer-HPMA	 paclitaxel	
copolymer	
targeted	drug	delivery	with	enhanced	
antitumor	efficacy		
targeted	drug	delivery	system	
	
HA	 oligomer-HPMA	 copolymer	
conjugated	 paclitaxel	 targeted	 to	
[369]	
	
[370]	
	
[371]	
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Paclitaxel	
	
amphiphilic	 HA-deoxycholic	 acid	
conjugated	paclitaxel	
HA-paclitaxel	conjugate	
	
HA-	paclitaxel	conjugated	micelles	
redox-responsive	 polymeric	
paclitaxel	HA	conjugate	
HA	nano	particle	directed	cytosolic	
paclitaxel	prodrug	delivery	
	
multi-functional	 tLyP-1-hyaluronic	
acid-paclitaxel	conjugate	
paclitaxel-glycyrrhetinic	 acid-graft-
HA	conjugate	synergistic	targeting		
CD44-overexpressing	ovarian	tumors		
Micellar	 targeted	 intracellular	
delivery	of	paclitaxel	
targeting	 of	 human	 squamous	 cell	
carcinomas	of	the	head	and	neck	
Intracellular	antitumor	targeting	
Intracellular	antitumor	drug	delivery	
	
HA-paclitaxel	 prodrugs	 for	 direct	
cytosolic	 delivery	 and	 enhanced	
antitumor	activity		
Broad	anti-cancer	treatment	
	
Improved	 anti-tumor	 activity	 and	
safety	delivery	of	paclitaxel	
	
[372]	
	
[373]	
	
[374]	
	
	
[375]	
[376]	
	
[377]	
	
[378]	
siRNA	 hydrophobized	 HA-spermine	
conjugates	
tumor-targeted	 delivery	 for	 efficient	
receptor-mediated	siRNA	delivery	
[379]	
Cisplatin	 HA-cisplatin	conjugate	
HA-Cisplatin	Nanoparticles	
Fibrin	gels	loaded	with	cisplatin	and	
cisplatin-hyaluronate	complexes	
Intralymphatic	chemotherapy	
Lung	Cancer	
subcutaneous	 human	 melanoma	
treatment	system	
[380]	
[381]	
[382]	
 
5. Therapeutic Properties of Platelet Rich Plasma 
 The reparative properties of platelet rich plasma (PRP) are controversial and based on 
its ability to provide supraphysiologic levels of essential growth factors which act as a 
regenerative stimulus promoting reparative processes in tissues which have an intrinsically 
low healing capacity [383] The alpha-granules of platelets contain platelet-derived growth 
factor (PDGF), transforming growth factor  beta (TGF-β), platelet factor interleukin-1 (IL-
1), platelet-derived angiogenesis factor (PDAF), vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF) and insulin-like growth factor (IGF) all of which have the 
ability to promote tissue repair [384]. 
 
 PDGF stimulates blood vessel formation along with PDAF and VEGF from existing 
vessel networks and thus contributes to tissue repair processes.  PDGF also stimulates cellular 
proliferation and migration of fibroblasts, osteoblasts, tenocytes, vascular smooth muscle cells. 
Platelet-derived IL-1 stimulates cytokine production of vascular smooth muscle cells, 
indicating that it may regulate cytokine networks during tissue repair processes [385]. TGF-β is 
a multifunctional cytokine of the TGF-β superfamily with the ability to promote synthesis of 
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major ECM components such as PGs and collagen by many cell types thus contributing to 
tissue repair and regeneration.  Overexpression of TGF-β however can also lead to fibrosis 
[386] and tumour development [387], and it  has crucial roles to play in the regulation of stem 
and T-cell differentiation [388].  PRP has anti-inflammatory, chondroprotective and potential 
regenerative properties stimulated when TGF-β, PDGF, EGF, VEGF, FGF, and IGF are 
released upon de-granulation.  These growth factors stimulate cartilage regeneration [389] and 
inhibit the actions of inflammatory mediators such as IL-1β [390].  PRG4 also inhibits adhesion 
of inflammatory cells to the articular surface reducing cartilage inflammation that can 
potentially lead to de-polymerisation of HA and loss of its lubricative properties and further 
degradative changes in the articular cartilage.   
 
 Pilot studies on the clinical efficacy of intra-articular PRP in the treatment of knee OA 
demonstrated clinical improvement in terms of self-reported pain and functional capacity with 
little or no adverse effects [391]. A systematic review, which included data from six 
randomised controlled trials comparing the effectiveness of PRP with other intra-articular 
injections, exercise or analgesia for a minimum of 6 months PRP produced statistically 
significant improvements in WOMAC scores for up to 12 months [392, 393]. Adverse events 
with PRP treatment were not significantly increased in comparison with other knee OA 
treatments consistent with earlier studies using PRP as an intervention in knee OA [393-395].  
Studies with intra-articular HA injections with PRP have indicated that younger patients with 
mild OA benefitted more than older patients with established OA [396].  The PRP formulation 
PRGF-Endoret has been shown to provide superior pain relief than HA [397].  Randomized 
controlled clinical trials in 2015 and 2017 however failed to show that PRP gave superior 
clinical benefit than HA in the treatment of OA [398].  AAOS guidelines do not currently 
recommend for or against the use of PRP for knee OA.  However a randomized controlled 
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clinical trial conducted in 2016 showed HA and PRP-HA injections had promise as a 
therapeutic combination for the treatment of knee OA [399]. 
 
5.1 PRP as a therapeutic treatment for mild to moderate knee OA: the added benefit of 
combined HA-PRP treatment.   
 While PRP and HA are both used as individual therapeutic treatments for mild to 
moderate OA, when used in combination, a synergistic effect has been reported with HA 
inducing the release of growth factors from PRP [400].  These promote anabolic responses that 
improve cartilage regeneration [401]  and joint function [402].  Inclusion of a cellular matrix 
along with PRP-HA intra-articular injections is reported to further improve long term 
beneficial effects in over 50% of patients avoiding surgery in 80% of cases at 4 year follow up 
[403].  Randomised controlled clinical trials comparing, PRP, HA and PRP+HA for the 
treatment of mild-moderate OA confirmed these beneficial aspects of using the combined 
treatment [399, 404] although PRP did not offer superior visco-supplementation to HA [394].  A 
Meta-analysis of randomized controlled trial data confirmed the efficacy and safety of PRP 
injections for the treatment of knee OA [405]. American College of  Rheumatology (ACR) 
and Osteoarthritis Research Society International (OARSI) guidelines on the use of PRP and 
HA intra-articular injections for the treatment of knee OA (Kjellgren-Lawrence grade II-III) 
state that accurate phenotyping and selection of patients should be mandatory in future 
randomized controlled trials [26]. 
 
 As already stated, the therapeutic properties of PRP are based on the presence of 
PDGF, TGF-β, VEGF, IGF-I, PF4, EGF, HGF and SDF-1α stored in the platelet a-granules 
[406].  The potential for variable results in therapeutic applications using such a complex 
biological mixture is to be expected, which may explain some of the inconsistent results 
reported for PRP treatment.  The standardization of procedures for the use of PRP and 
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selection criteria for subjects who will maximally benefit from the procedure will hopefully 
minimize this biological spread. Although PRP is reported to provide pain relief and 
improved joint function its mechanism of action is appears not to involve effects due to 
enhancement of MSC-mediated hyaline cartilage formation.  PRP added to infrapatellar fat 
pad-adipose stem cells and bone marrow MSCs cultured in high density pellet cultures did not 
enhance cellular proliferation or matrix production [407].   
 
6. The promise of MSCs for the treatment of OA 
 Intra-articular MSCs and chondroprogenitor cells have yielded promising results in 
cartilage repair in animal OA models and in preclinical studies on the treatment of knee OA.  
Chondroprogenitor cells transfected to produce elevated TGF-β levels  are currently under 
phase III evaluation in clinical trials for the treatment of grade II and III Kjellgren and 
Lawrence OA patients.    
6.1 Animal models of OA which demonstrate the utility of MSCs.   
 Repair and regeneration of the knee joint meniscal fibrocartilages of the knee has been 
examined by intra-articular injection of MSCs from adipose tissue, bone marrow, synovium, 
or meniscus alone or in combination with implantable or injectable scaffolds [408]. 
Fibrochondrocytes, chondrocytes, and transfected myoblasts [409] seeded into various 
combinations of bioscaffolds have also been examined for their abilities to carry out meniscal 
repair and regeneration [408]. In-vitro and in-vivo preclinical and laboratory based studies 
using allogeneic cells for cartilage repair have been just as successful as studies employing 
autologous cells [410, 411]. Implantation or injection of cell-seeded scaffolds has increased tissue 
regeneration and led to better structural organization of the repair tissue compared to the use 
of a scaffold alone. Intra-articular administration of MSCs in a caprine model of OA resulted 
in a pronounced regeneration of the medial meniscus however degeneration of the articular 
cartilage, osteophytic remodeling, and subchondral sclerosis were also reduced with MSC 
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treatment compared to vehicle alone [412].  Intra-articular injections of MSCs in sheep OA 
models retards the progression of OA and promotes repair of 60mm full thickness cartilage 
defects [413] and stimulates cartilage regeneration in a sheep OA model induced by complete 
resection of the anterior cruciate ligament and medial meniscus [414].  MSCs administered with 
Hyaff-11, (Hyaff-11® is a 3D fibrous membranous scaffold material composed of a benzyl 
ester of HA [415]) in a sheep meniscectomy OA model resulted in a reduction of inflammation 
in cartilage, meniscus , and synovium and produced a reversal of fibrotic and hypertrophic 
tissue changes which normally occur in this model without MSC administration.  Cartilage 
degeneration was also prevented and regeneration of the excised meniscus was prominent [416].  
The knee joint menisci protect other knee joint tissues from degenerative changes thus repair 
of the menisci is important for the global health and function of the knee-joint[130, 417]. . 
 
 MSCs are present in multiple niches in the knee-joint in subchondral bone, articular 
cartilage, meniscus, synovial fluid, synovium and the adipose fat pad. Developmental studies 
demonstrate that MSCs have chondrogenic roles during embryogenesis and diarthrodial joint 
development [250], and also suggest that synovium-derived MSCs have migratory properties 
homing to sites of cartilage damage where they attempt to undertake cartilage repair in 
adulthood [418].  Injection of MSCs with HA in a rabbit OA model promoted the migration of 
MSCs to cartilage.  It has been proposed that priming of progenitor cells with HA modulates 
cell homing and favours their attachment to and integration with articular cartilage, a feature 
conducive to cartilage repair processes in the treatment of OA [419].  A sheep OA model has 
also demonstrated that intra-articular injection of allogeneic  adipose derived 
MSCs combined with HA efficiently blocked OA progression and promoted cartilage 
regeneration [420].  Furthermore, intra-articular injection of allogeneic MSCs with HA in an in-
vivo anterior cruciate ligament transection rabbit model of OA, the joint surface showed less 
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cartilage loss and surface abrasion after MSC injection compared to tissues receiving HA 
injection alone thus the MSCs apparently reduced the progression and severity of OA [421]. 
 
 Chondrogenic priming of bone marrow stromal MSCs in the laboratory is reported to 
improve their anabolic ECM gene expression profiles and the development of their ability to 
undertake cartilaginous repair within cartilage defects in a full thickness cartilage defect 
model in sheep [422]. Further studies have shown that chondrogenic pre-conditioning of MSCs 
enhanced cartilage regeneration through epigenetic methylation modifications of Nanog and 
Oct4 in committed chondrogenic cell populations suitable for the treatment of OA cartilage 
lesions [423]. FGF-2 and FGF-18 have also been used to pre-condition bone marrow derived 
stromal MSCs promoting cellular proliferation for expansion of MSC numbers and guiding 
them to appropriate chondrogenic repair phenotypes in-vitro [424, 425].  This suggests that this 
step could improve their cartilage repair capabilities if FGF-2/FGF-18 and MSCs were co-
administered intra-articularly.  This possibility has not been considered as a potential 
mechanism whereby MSC cell proliferation could be enhanced in-situ and the cartilage repair 
properties of undifferentiated stem cells could be guided to a reparative phenotype. If MSC 
differentiation could be manipulated as suggested by the findings of in-vitro experiments 
conducted with these components [425] this would be expected to be beneficial in the treatment 
of OA. 
 
6.2 Human pre-clinical studies on MSCs.   
 Adult MSC-based tissue engineering is a promising technology for the development of 
a transplantable cartilage replacement to improve joint function [8].  Delivery of MSCs to the 
OA affected knee could be undertaken by intra-articular injection or by graft of an engineered 
construct seeded with MSCs.  Thus a 3D construct with mechanical properties appropriate for 
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the weight-bearing function of the joint can be designed for specific applications to support 
the use of MSCs for regenerative procedures.   
 
 An innovative strategy has been developed using  hyperbranched multi-acrylated 
poly(ethylene glycol) macromers (HP-PEGs) and thiolated hyaluronic acid (HA-SH) as an 
injectable stem cell delivery and retention platform to deliver encapsulated  adipose-derived 
stem cells (ADSCs) to treat diabetic wounds in a diabetic murine animal model.  This strategy 
yielded enhanced wound healing of diabetic wounds which have a notoriously poor repair 
capability similar to OA lesions in articular cartilage.  This polymer has a proven ability to 
maintain stem cell stemness  and viability  and ability to secrete trophic repair factors 
conducive to tissue regeneration. Thus ADSCs maintained their regenerative ability when 
delivered into wound sites using this hydrogel. Such an approach resulted in remarkable 
enhancement of diabetic wound healing, including inhibition of inflammation, enhanced 
angiogenesis and re-epithelialization. This approach represents a significant advance in the 
healing of one of the most serious problematic clinical wounds and could be adapted to an 
orthobiological visco-supplementation format for the treatment of OA[426]. 
 
 Another innovative approach is the use of resident MSCs harvested from OA knee 
arthroscopic flushing fluids recovered from initial clinical knee examinations.  These cells 
were incorporated into HP-PEG/HA-SH hydrogels and delivered into a rat full thickness 
cartilage defect model and induced repair after an 8 week repair period.  This study 
demonstrated the repair capability of knee-joint MSCs harvested in such a manner and the 
effectiveness of the HP-PEG/HA-SH hydrogel delivery system for cartilage repair warranting 
further studies in an orthobiological cartilage repair format[427].  
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 A further approach for the delivery of therapeutic cells for cartilage repair is the use of 
bioadhesives to deliver these cells to the defect site.  Pullulan has been used to successfully 
attach MSCs to fibrillated cartilage regions dramatically improving their retention in eroded 
articular cartilage lesions where the MSCs promote cartilage repair.  Pullulan is a 
biocompatible and effective cytoadhesive material for tissue engraftment of MSCs. Prolonged 
exposure to pullulan had no negative impact on the phenotype, viability and differentiation 
potential of the cells [428] with MSCs maintaining a stable phenotype in terms of metabolic 
activity, proliferation and differentiation. Further bioadhesives which have strong wet-
adhesive properties have been developed to avoid suturing in abdominal and heart surgery 
should also be of application in this area of bioadhesive mediated cell delivery for cartilage 
repair.   
 
6.3 Manipulation of the MSC phenotype using bioscaffolds.   
 An interesting approach inspired by the cell directive capability of GAGs of PGs has 
been developed using acellular implants that can become colonized by resident stem cell 
populations in tissues [429].  Thus bioactive signals and scaffolds can actively recruit 
endogenous stem cells which potentially have the capacity to repair OA lesions.  As proof of 
principle the authors showed that endogenous stem cells actively homed to defect sites and 
could be used to regenerate the surface cartilage in a rabbit model [430]. Attempts have been 
made to model the chemotactic responses of different joint stem cell populations in order to 
understand how they can be induced to undertake chondrogenesis and cartilage repair [431].  
HA has cell interactive properties and is known to promote cell migration. This has led to the 
development of HA binding scaffolds which may provide an environment conducive to 
cartilage repair processes [432].  Nano-fibres have also been developed which stimulate 
chondrogenesis and cartilage repair [433]. Furthermore, CS- bioscaffolds have been shown to 
direct stem cell differentiation in-situ and is of potential exploitation in improved cartilage 
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repair strategies [47]. Transplantation of MSCs seeded in such biomatrices represents a 
promising strategy [434] given the high proliferative capacity of MSCs and their potential to 
differentiate into cartilage-producing cells [435] however further work is required before this 
will become a modality suitable for clinical evaluation [436].  Besides articular chondrocytes, 
cells from the synovial membrane, fat pad, and meniscus all have variable abilities to form 
cartilage  [437].  However in order to obtain sufficient cell numbers for preclinical evaluation 
these cells need expansion in-vitro under conditions which direct the cells to a chondrogenic 
phenotype.  A co-culture approach of MSCs with cartilaginous cells may represent a simpler 
approach [410, 438]  for the expansion of chondrogenic cell numbers. A phase I/II  clinical study 
has shown that intra-articular injection of expanded autologous bone marrow MSCs is a safe 
procedure for the treatment of moderate to severe knee OA [439]  research is on-going to 
perfect this technique [440]. 
 
6.4 Human clinical trials with intra-articular MSCs and chondroprogenitor cells. 
 Clinical trials using intra-synovial injection of MSCs for the treatment of advanced 
OA of the knee were started in 2013 [441] and are ongoing in 10 European Centres using 
patient-derived adipose stem cells (https://cordis.europa.eu/result/rcn/193066_en.html  
European Union 2018, adipoa2-z-fold-brochure-jpg.jpg). In 2017, INVOSSA™ (Kolon 
TissueGene) TGF-β transfected cells were approved for the treatment of knee OA in South 
Korea [442]. This allogeneic cell therapy utilised chondrocytes transduced with a retrovirus 
overexpressing TGF-β which is irradiated to prevent any risks of insertional mutagenesis.  
These genetically modified cells expressed TGF-β at therapeutic levels to promote cartilage 
repair.  On Nov 21st 2018, an FDA approved Phase III placebo controlled double blind trial 
was initiated in the USA using INVOSSA™(TG-C) allogeneic primary chondrocytes 
transduced to express TGF-β1 for the treatment of Kjellgren and Lawrence grade II and III 
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OA [https://www.prnewswire.com/news-releases/kolon-tissuegene-doses-first-patient-in-us-
phase-iii-clinical-trial-300754257.html].  Phase II trials with this product already conducted 
yielded encouraging results in terms of pain relief and improvements in clinical indices of 
knee-joint function [443].  This phase III trial using INVOSSA™(TG-C) has 1020 patients 
enrolled and will be conducted in 60 clinical centres throughout the USA. Although expert 
formulated guidelines indicate that visco-supplementation is only appropriate for cases of 
mild OA, [26, 444] it is conceivable that stem cells or engineered chondrocytes could be 
delivered in a visco-supplement to treat more advanced stages of OA - localising the 
administered cells at the articular surface in an effort to promote focal cartilage regeneration 
and recapitulating the early stages of rudiment and diarthrodial cartilage development [43, 44, 
250] (Figure 8).  Such a proposal has considerable merit and is worthy of future investigation.  
Furthermore, a recent review of the use of GAG copolymer hydrogels and bioscaffolds has 
demonstrated their ability to direct stem cell differentiation and promote anabolic repair 
processes [47].  Such processes could potentially be incorporated into a visco-supplement 
preparation to promote cartilage re-surfacing and chondrogenic repair.  Several novel options 
therefore exist in the development of new generation visco-supplement therapeutics which 
certainly are worthy of further examination. 
 
7. Future Research 
Pre-clinical and animal model based studies have demonstrated that neo-aggrecan has useful 
water imbibing properties and is more resistant to proteolytic degradation than native 
aggrecan.  Recombinant domain-I and domain V of perlecan also have useful properties in 
BMP-2 and FGF-2 delivery applicable to cartilage and bone regeneration and anti-angiogenic 
properties of potential application in neurovascular therapeutic applications respectively.  
Continued development of these neo-PGs will bring them a further step closer to clinical 
application.  Neo-lubricin also has impressive properties as a visco-supplement and has 
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proposed in this review for prospective inclusion as a component to augment HA visco-
supplement formulations  to improve their performance in an orthobiological approach to the 
treatment of knee OA. PRP and MSCs also have important biological properties which 
warrant their inclusion in such multifunctional orthobiological formulations.  It will be 
interesting in future studies to observe whether protocols are developed using such a 
therapeutic approach. 
 
7.1 The critical importance of patient selection in visco-supplementation procedures.   
 In introductory comments to this review we indicated the importance of appropriate 
patient selection to select individuals affected by mild to moderate OA who would optimally 
benefit from these procedures. This has been re-iterated by guidelines on the use of PRP in the 
treatment of OA released by the ACR and OARSI mandated that future clinical trials with 
PRP should follow strict patient selection guidelines with the procedure only being offered to 
Kjellgren and Lawrence grade II and III OA patients since these were the patients which 
would optimally benefit from this procedure [445]. These comments were made in response to 
inconsistent reports of the efficacy of PRP in the treatment of knee OA possibly due to 
inappropriate patient selection. Similarly, despite numerous studies clearly showing the 
beneficial effects of HA injections for pain reduction and recovery of joint function reports 
still persisted questioning the efficacy and utility of intra-articular injection of HA visco-
supplementation procedures possibly fuelled by inconsistent findings from clinical trials not 
conducted in a standard format [446].  Furthermore, in 2013 AAOS clinical practice guidelines 
for the treatment of knee OA did not recommend using HA for patients with symptomatic 
knee OA and these guidelines also stated that there was inconclusive evidence to recommend 
for or against the use of intra-articular corticosteroids to treat knee OA [447]. Robust debate 
continued in this area fuelled by the inconsistent findings of some studies until in 2018 
EUROVISC issued guidelines on how clinical trials should be conducted on HA 
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viscosupplementation procedures [448].  Furthermore, in July 2018, a key opinion leader panel 
discussion by ten leading expert physicians made two major recommendations. 1. "Visco-
supplementation with the use of hyaluronic acid injection is a treatment option for knee OA 
and can provide lubrication and elastic shock absorption, leading to potential pain relief, 
improved function, and reduced stiffness”. 2.The panel also concluded that “visco-
supplementation with HA injections represented a viable, cost-effective, and safe alternative 
for the treatment of knee OA" [449]. 
 
7.2 Orthobiologics: an emerging, promising, therapeutic modality  
 As we have outlined earlier, HA, has established outstanding credentials as an agent 
for the improvement of articular lubrication and the maintenance of the visco-elastic 
properties of synovial fluid which provides weight bearing and pain alleviation in OA. A 
number of pharmacologic compounds developed over the last five decades have also usefully 
treated some degenerative features of OA articular cartilage. These compounds include 
corticosteroids, NSAIDs, DMAODs and anti-oxidants.  Each of these have intrinsic beneficial 
properties in their own right in the treatment of OA but in isolation they are incapable of 
alleviating all OA symptomatology. A recent approach has been to use some of these 
compounds to augment HA viscosupplements in order to improve their therapeutic 
performance in the treatment of OA. Addition of these compounds is generally acknowledged 
to improve the therapeutic properties of HA viscosupplements compared to HA alone.  PRP 
has also been shown to act synergistically with HA in viscosupplements improving the 
efficacy of HA formulations in the treatment of OA. MSCs have also yielded promising 
results in animal models and in preclinical studies in the treatment of knee OA and are 
currently under evaluation in clinical trials for the treatment of grade II and III Kjellgren and 
Lawrence OA patients.  mLUB15, a mimetic neo-lubricin also has useful properties in 
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cartilage lubrication and surface protection and could usefully augment HA viscosupplement 
formulations to improve their therapeutic performance.  
 
 Recent findings in clinical studies on the therapeutic use of visco-supplementation 
with HA for the treatment of OA have yielded promising but heterogenous findings of 
variable quality. With so many formulations of HA available commercially for intra-articular 
injection, variable weight ranges, different concentrations of HA formulations and non-
uniform clinical trial formats this was a somewhat predictable outcome. Thus there is a need 
for more robust studies to determine the place of visco-supplementation in the management of 
knee OA but sufficient positive findings to warrant continuing such studies.  To this end 
EUROVISC recently issued guidelines on how clinical trials should be conducted on the use 
of HA for visco-supplementation [448]. One option to improve the performance of visco-
supplementation was to augment such visco-supplement formulations with growth factors, 
neoPG biomimetics and therapeutic cells to promote maintenance of the lubricative properties 
of articulating joints, control inflammation and provide an environment conducive to 
proliferation of resident cell populations for the replenishment of matrix components and 
repair of cartilage defects aided by the therapeutic cells provided in the augmented visco-
supplement formulation.  A comparison of the efficacy of intra-articular corticosteroids with 
HA for knee OA showed each were equally effective at pain relief over 1-4 weeks after 
injection while HA had a superior effect over 5-13 weeks [259]. Augmentation of triamcinolone 
in HA visco-supplements also improved WOMAC  (The Western Ontario and McMaster 
Universities Osteoarthritis Index) and VAS (Visual analog scale for pain) scores after 1 week 
compared with HA alone [316].  Recent trials comparing triamcinolone with HA found HA to 
be more effective at pain reduction and it also increased range of joint motion [66].  
Combined with the outstanding performance of high molecular weight HAs in the lubrication 
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of articular cartilage these added biological properties further establish HA as an important 
component of visco-supplement formulations. 
 
7.3 The outstanding performance of high molecular weight HA as a visco-supplement.  
 Cross-linked high molecular weight HA preparations such as Hylan G-F 20 [450] and 
Durolane NASHAs [269] and similar HA products [451] with their higher molecular weights, 
improved visco-elastic properties, improved residence times and high injection concentrations 
which facilitate single injection protocols have clearly provided an improvement in the 
clinical treatment provided by visco-supplementation. A recent comparison of the efficacy of 
corticosteroids, visco-supplementation, PRPs, and MSCs for improved joint function has 
shown that each have positive attributes [452]. Corticosteroid injections are recommended as a 
first-line treatment for OA patients resistant to other non-surgical treatments such as NSAID 
medication, physical therapy, weight loss, and an acceptable amount of activity modification. 
However corticosteroid injections are not recommended for prolonged usage. Intra-articular 
injections of HA are recommended to replace the deficient levels of endogenous HA in OA 
knees and to allow the recovery of efficient joint articulation  and associated pain-relief due to 
the improved weight-bearing provided by the visco-elastic properties of the injected HA. PRP 
has anti-inflammatory, chondroprotective and regenerative properties due to TGF-β, PDGF, 
EGF, VEGF, HGF, FGF and IGF which are released upon de-granulation when PRP is 
injected as a supplement in HA intra-articular injections. These growth factors stimulate 
cartilage regeneration [389] and inhibit the actions of inflammatory mediators such as IL-
1β [390]. It may well be that a combined biotherapeutic approach such as that proposed in a 
multifunctional orthobiological may well provide an effective new approach to the treatment 
of OA. This option is certainly worthy of further evaluation in future research. 
 
8. Conclusions 
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1) By understanding how the core proteins and GAG side chains of native PGs contribute 
to their functional properties in tissues it has been possible to identify critical features 
which need to be built in to neo-PG design to emulate these features. 
2) While native PGs such as aggrecan rely on macro-aggregate formations to convey 
biophysical properties to tissues, it has been possible through innovative design to 
prepare more robust neo-aggrecans of smaller dimensions and with improved water 
retention and matrix stabilizing properties. These neo-aggrecans are less susceptible to 
proteolytic degradation in-situ thus their biological half-lives are increased relative to 
the native PGs making them amenable to many applications in repair medicine. 
3) Retention of biopolymers within bio-scaffold frameworks, or in the squeeze-film 
during boundary lubrication, are also important considerations in particular 
applications and interactive peptides have been included in neo-PG design to convey 
these interactive retentive properties.  The interactive properties of these molecules 
with other endogenous ECM components within the superficial regions of articular 
cartilage further support their retention at the tissue’s surface.  
4) Development of many combinations of GAG copolymers, GAG peptidoglycans, nano-
delivery systems, bioactive visco-supplements testify to the diverse innovative 
applications possible. 
5) Recombinant PGs have specific targeting properties which neo-PGs cannot match, 
thus they will also continue to be of application in specific repair strategies..  
6) Viscosupplementation is a valuable procedure in the treatment of mild to moderate 
knee OA.  Many strategies and formulations with HA have been developed in a 
procedure known as orthobiological visco-supplementation.  These are multifunctional  
formulations which can also contain PRP, MSCs neo-PGs such as mLUB15 and 
growth factors/anti-oxidants.   
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